<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">	<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">		<head>			<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />			<meta http-equiv="X-UA-Compatible" content="IE=edge" />			<link rel="shortcut icon" href="dailymed/images/favicon.ico" />			<meta name="ROBOTS" content="NOFOLLOW" />				<script type="text/javascript" src="/dailymed/scripts/1.10.2/jquery-1.10.2.min.js"></script>	<script type="text/javascript" src="/dailymed/scripts/jquery-ui/jquery-ui.min.js"></script>	<script type="text/javascript">		var jQuery_1_10_2 = $.noConflict();	</script>	<link rel="stylesheet"   href="dailymed/scripts/jquery-ui/smoothness/jquery-ui.min.css" type="text/css" />	<link rel="stylesheet"   href="dailymed/styles/base-.min.css?v=1.2" type="text/css"  />		<script src="/dailymed/scripts/drop_down-.min.js" type="text/javascript"></script>	<script src="/dailymed/scripts/shared-.min.js" type="text/javascript"></script>	<!--[if IE]>	<link rel="stylesheet" type="text/css" href="dailymed/styles/ie-hacks-.min.css" />	<![endif]-->		<script type="text/javascript" src="/dailymed/scripts/1.3.2/jquery-.min.js"></script> 	<script type="text/javascript" src="/dailymed/scripts/autocomplete/jquery.autocomplete.min.js"></script>	<script type="text/javascript">		$(document).ready(function(){						// check to see if autocomplete plugin has been loaded by looking for existance of "autocomplete" function in jQuery object			if( $.fn.autocomplete ) {  				// THE PLUGIN HAS BEEN LOADED!				//alert(" autocomplete is already loaded! great! ");			}			else {				// reinsert the script tag into the head to load the autocomplete plugin								//alert(" we need to load in autocomplete..." );								$("head").append('<script type="text/javascript" src="/dailymed/scripts/autocomplete/jquery.autocomplete.min.js" />');					}						// actually activate autocomplete			$("#startswith").autocomplete("/dailymed/autocomplete.cfm?key=search",{				width: 275,				selectFirst: false,				cacheLength:1,				max:200,				matchSubset:false,				delay:300,				minChars:3			});		});	 	</script>			<link rel="stylesheet"   href="dailymed/scripts/autocomplete/jquery.autocomplete-.min.css" type="text/css" />	  	<noscript>Your browser does not support JavaScript!</noscript>														<title>LETROZOLE TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.]</title>			<link rel="alternate" type="application/rss+xml" href="dailymed/labelrss.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02"			title="RSS Feed for LETROZOLE TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.] Label"/>			<link rel="bookmark" href="lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02" title="LETROZOLE TABLET [BRECKENRIDGE PHARMACEUTICAL, INC.]" />						<link rel="stylesheet" type="text/css" href="fdastyles/spl-.min.css" />							<link rel="stylesheet" type="text/css" href="styles/layouts/slidingdoors-.min.css" />						<link rel="stylesheet" href="styles/colorbox-.min.css" type="text/css" media="screen" />			<script language="javascript" type="text/javascript" src="scripts/jquery.colorbox-min.js"></script>			<script type="text/javascript" src="scripts/autocomplete/lib/jquery.bgiframe.min.js"></script>			<script type="text/javascript" src="scripts/autocomplete/lib/jquery.dimensions-.min.js"></script>		</head>		<body>							<div id="controls"><ul>    	<li><a class="skipicon1" href="#druglabelcontent" title="Skip to DrugLabel content paragraph">Skip to DrugLabel content</a></li>	<li><a class="skipicon2" href="#dmsections" title="Skip to DrugLabel sections paragraph">Skip to DrugLabel sections</a></li>   </ul></div>  <div id="dailymedbanner">  		<div id="brandimage">        <img src="/dailymed/images/DM_LOGO_HEADER.png" alt="DailyMed Logo Header image" />        </div>        <div id="top">          <h1>Daily            <span>Med</span>          </h1>          <h2>            <span>Current </span>            <span>Medication </span>            <span>Information</span>          </h2>        </div>  </div>						<div id="actions">	<div id="options">		<h2>Options</h2>		<ul id="dmnav">	      		<li>					<a 	title=" Link to DailyMed Home "						href='/dailymed/about.cfm'						id="home">Home</a>				</li>	      		<li>					<a 	title=" Link to E-mail Label Information "						href="dailymed/emailWebLink.cfm"						id="email">E-mail Label Information</a>				</li>				<li><a 	class="rightarrow"						href="#"						title="Links to download options">Downloads</a>					<ul>						<li>							<a	title=" Link opens new window to download all drug labels "								href="dailymed/downloadLabels.cfm">Download All Drug Labels</a>						</li>                        <li>                        	<a	title=" Link opens new window to download all indexing files"                             	href="dailymed/downloadIndexing.cfm">Download All Indexing Files</a>                        </li>                        <li>                        	<a	title=" Link opens new window to download all mapping files"                             	href="dailymed/downloadMappingFiles.cfm">Download All Mapping Files</a>                        </li>                    	<li>                        	<a	title="Link to download FDA SPL Stylesheets"                            	href="http://www.fda.gov/downloads/ForIndustry/DataStandards/StructuredProductLabeling/UCM362812.zip">Download FDA SPL Stylesheets</a>                        </li>												<li>							<a	title=" Link opens new window to download this label (XML) "								href="dailymed/getFile.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02&amp;type=zip&amp;name=LETROZOLE">Download this Label(XML)</a>						</li>                        <li>						                        					</ul>				</li>								<li><a 	title="SPL History"						href="dailymed/splshistory.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02"						id="splhistory">SPL History </a>				</li>				<li><a 	title="Link to Print this Label"						href="dailymed/fda/fdaDrugXsl.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02&amp;type=display"						id="printitem"						target="_blank"> Print this Label </a>				</li>                <li>                				                    <a	title="Download PDF of this Label"                             href="dailymed/getFile.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02&amp;type=pdf&amp;name=63e54b62-a30d-4a56-9215-75e7a0b0bf02"                            id="downloadpdf"> Download this Label (PDF)</a>                                                               </li>        					      	    <li>						<a	title=" Notify of Updates "						href="dailymed/rsshome.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02"						id="rss">Notify of Updates</a>				</li>	      		<li>					<a	title=" Contact Us "						href="dailymed/contactUs.cfm"						id="contact">Contact Us</a>				</li>                <li>					<a	title=" Help "						href="dailymed/help.cfm"						id="help">Help</a>				</li>                <li>					<a	title=" Web Services "						href="dailymed/help.cfm#webservices"						id="help">Web Services <img src="/dailymed/images/new.gif" alt="New Web Services" /></a>				</li>                <li class="new-option">                	<a	title=" Browse Drug Classes "                    	href="dailymed/browseClasses.cfm"                        id="browse">Browse Drug Classes                    </a>                                    </li>				<li><h2>Additional Resources</h2></li>                <li>                	<a 	class="rightarrow"                		href="#"	                    title="Links to DailyMed presentations and related material">DailyMed Presentations and Related Material</a>                	<ul>                    	<li>                        	<a	href="http://videocast.nih.gov/Summary.asp?File=18134"                            	title="SPL/DailyMed Jamboree Workshop Videocast">SPL/DailyMed Jamboree Workshop Videocast</a>                        </li>                        <li>                        	<a	href="http://www.nlm.nih.gov/mesh/spl_workshop.html"                            	title="SPL/DailyMed Jamboree Workshop Slides">SPL/DailyMed Jamboree Workshop Slides</a>                        </li>                   		<li>                   			<a 	href="http://spl-work-group.wikispaces.com/Bibliography+-+Articles+containing+SPL"                            	title="Articles and Papers about SPL and DailyMed">Articles and Papers about SPL and DailyMed</a>                   		</li>                    </ul>                </li>                <li>                    <a	href="http://www.fda.gov/oc/datacouncil/spl.html"                        title="Link opens in a new window for FDA SPL Resources"                        target="FDA">FDA Structured Product Labeling Resources and Stylesheets                    </a>                </li>				<li>					<a	id="splimagesspec"						href="dailymed/splimagesspec.cfm"						target="SPLIMAGESPEC"						title="SPLIMAGE Specifications">SPLIMAGE Specification Version 3.0.2  </a>				</li>				<li>					<a	id="report"						href="http://www.fda.gov/medwatch/how.htm"						target="FDA"						title="FDA Page to Report Adverse Event">Report Adverse Event</a>				</li>																				    <li><a href="http://www.nlm.nih.gov/search/medlineplus?query=LETROZOLE" title="Link opens new window to MedlinePlus Information" target="medlinePlus">MedlinePlus Information</a></li>			    <li><a href="http://www.clinicaltrials.gov/ct/search?submit=Search&amp;term=LETROZOLE" title="Link opens new window to Find Clinical Trials" target="clinicalTrials">Find Clinical Trials</a></li>				<li><a href="http://www.drugbank.ca/search/search?query=APRD01066" title="Link opens new window to University of Alberta DrugBank" target="drugBank">Biochemical Data Summary</a></li>			    <li><a href="#" class="rightarrow" title="Links to Search PubMed Articles">Search PubMed Articles</a>				  <ul>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=LETROZOLE[All Fields]" title="Link opens new window for All Citations" target="pubmed">All Citations</a></li>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=LETROZOLE/AE" title="Link opens new window for Adverse Effects" target="pubmed">Adverse Effects</a></li>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=LETROZOLE/TU"  title="Link opens new window for Therapeutic Use" target="pubmed">Therapeutic Use</a></li>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=LETROZOLE/PD" title="Link opens new window for Pharmacology" target="pubmed">Pharmacology</a></li>					<li><a href="http://www.ncbi.nlm.nih.gov/sites/entrez?DB=pubmed&amp;term=LETROZOLE[All Fields] AND Clinical Trial[ptyp]" title="Link opens new window for Clinical Trials" target="pubmed">Clinical Trials</a></li>				  </ul>			    </li>				<li>					<a href="http://toxnet.nlm.nih.gov/cgi-bin/sis/search/r?dbs+lact:@na+LETROZOLE" target="toxnet" title="Link opens new window for Presence in Breast Milk">Presence in Breast Milk</a>								</li>                <script> $(function() {			jQuery_1_10_2( "#dialog-confirm" ).dialog({			  resizable: false,			  modal: true,			  autoOpen: false,			  position: {				my: "center",				at: "center",				of: $("body"),				within: $("body")			  }			});					jQuery_1_10_2( ".disclaimer-link" ).click( function(event){				event.preventDefault();				jQuery_1_10_2( "#dialog-confirm" ).dialog( "option", "buttons", 					[						{							text: "Continue", 							click: function() {								jQuery_1_10_2( this ).dialog( "close" );								$( "a.rximage" )[0].click();							}						},						{							text: "Cancel", 							click: function() {								jQuery_1_10_2( this ).dialog( "close" );							}						}					]				);								jQuery_1_10_2( "#dialog-confirm" ).dialog( "open" );			});						$( ".rximage" ).colorbox({				rel:'rximage',				maxHeight:'100%',				maxWidth:'100%'			});		});</script><div id="dialog-confirm" title="Disclaimer" style="display:none;">  <p><span class="ui-icon ui-icon-alert" style="float: left;"></span>&nbsp;<strong>Disclaimer:</strong> These images are provided by the National Library of Medicine (NLM) and are not part of the official label.</p> </div>    	    	     </ul>		 		 	<div id="mdswitch">									<a  href="dailymed/drugInfo.cfm?id=45377&amp;dictionary=on"						title="Turn Dictionary Words On">						<img src="/dailymed/images/dictionaryon.jpg" alt="Turn Dictionary Words On"/>					</a>							</div>				</div>							<style type="text/css">		html body {		min-width:1024px;		}        .smallimage {            border: 1px solid ##ACBECE;        }</style>						    	    																																																								    	    	                             		       	                                                   <script>	$(function() {		$( '.splimage' ).colorbox({			rel:'splimage',			maxHeight:'100%',			maxWidth:'100%'		});	});</script>		            </div>			<div id="content">			<div id="searchpane">			<div id="search"><form action="/dailymed/search.cfm" name="searchform"><div class="divtable">    <div class="divtr">            <div class="divtd">Search :</div>            <div class="divtd">            	<label for="startswith" class="invisibletag">Enter a drug Name to search</label>                <input style="width:95%;"                type="text"                 id="startswith"                 name="startswith"                 title="enter a drug name to search"                  onclick="javascript:resetme()" /> &nbsp;                       </div>            <div class="divtd">              	<label for="go" class="invisibletag">Go</label>                <input type="image"                 src="/dailymed/images/goButton.gif"                 alt="Click this button to start your drug name search"                 title="Click this button to start your drug name search"                 id="go"/> &nbsp;            </div>            <div class="divtd80">            	<a href="dailymed/advancedSearch.cfm">Advanced Search</a>            </div>    </div>    <div class="divtr">    		<div class="divtd85">Limits:</div>            <div class="divtd85">                <input  class="searchoptions"  type="radio" name="searchdb" value="drugname" id="name-radio" title="Drug Name" />                <label for="name-radio" class="searchoptions">Drug Name</label>                <input  class="searchoptions"  type="radio" name="searchdb" value="ndc" id="ndc-radio" title="NDC Code" />               	<label for="ndc-radio" class="searchoptions">NDC Code</label>                <input  class="searchoptions"  type="radio" name="searchdb" value="drugclass" id="class-radio" title="Drug Class" />               	<label for="class-radio" class="searchoptions">Drug Class</label>                <input  class="searchoptions"  type="radio" name="searchdb" value="setid" id="setid-radio" title="SETID" />               	<label  for="setid-radio" class="searchoptions">SetId</label>            </div>    </div>    <div class="divtr">            <div class="divtd85">Label Type:</div>            <div class="divtd85" style="float:left;">                <input class="searchoptions" type="radio" name="labeltype" value="human" id="human-radio" title="Human Drugs" />               	<label for="human-radio" class="searchoptions">Human Drugs</label>                <input class="searchoptions" type="radio" name="labeltype" value="animal" id="animal-radio" title="Animal Drugs" />               	<label for="animal-radio" class="searchoptions">Animal Drugs</label>            </div>    </div>          </div></form></div>			</div>					<div id="rxnormlist">		<h3>RxNorm Names</h3>								<ul style="maring:0px; padding:0px;">				<li id="item1" style="padding:1px; margin:1px;">					  						<a 	id="viewrxnorm"							href="rxnormdata.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02"							onclick="rxnormpopup(this.href);return false;"							target="rxnorm" title="Link to Review RxNorm Normal Forms" >							<img src="images/closed.gif"								 alt="Icon attached Review or Hide All RxNorm Normal Forms Link"								 id="img_item1"								 border="0"								 style="clear:none;float:left">Review RxNorm Normal Forms</a>					  			  	</li>			 </ul>				</div>				<p class="DocumentTitle"><strong>LETROZOLE&nbsp;tablet</strong><br> [Breckenridge Pharmaceutical, Inc.] 	</p><br>			<div class="permalink">				<h3><strong>Permanent Link: </strong></h3><span><a href="lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02">http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=63e54b62-a30d-4a56-9215-75e7a0b0bf02 </a><span>			</div>												<div id="nlmdrugstatus">			<table border="4" width="100%" style="border: 1px solid rgb(142, 1, 10); padding: 0pt; float: right; margin-bottom: 0.75em; margin-top: 0.75em; position: relative; right: 0pt;">			<thead align="left" bgcolor="#F6F6F6" style="color:#8e010a; font-size:1.2em">			<tr>			<th scope="col">				<a class="anchor1" href="http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162063.htm" target="fda"			onclick="fdapopup(this.href);return false;" title="Document Type including Content of Labeling Type">			Category</a></th>			<th scope="col">				<a class="anchor1" href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs/ucm071816.htm" target="fda" onclick="fdapopup(this.href);return false;" title="SPL DEA Schedule">			DEA Schedule</a></th>			<th scope="col">			<a class="anchor1" href="http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/DataStandardsManualmonographs/ucm071826.htm" target="fda" onclick="fdapopup(this.href);return false;" title="Marketing Category">Marketing Status</a></th>			</tr>			</thead>			<tbody>			<tr>			<td scope="row"><strong>HUMAN PRESCRIPTION DRUG LABEL</strong></td>			<td scope="row"><strong></strong></td>			<td scope="row"><strong>Abbreviated New Drug Application</strong></td>			</tr>			</tbody>			</table>			<div id="disclaimer" >											</div>			</div>			<div id="dmsectionsfieldset"><fieldset><legend>Drug Label Sections</legend><div id="dmsections"><ul><li><a title="Description" href="#nlm34089-3" class="nlmlinktrue">Description</a></li><li><a title="Clinical Pharmacology" href="#nlm34090-1" class="nlmlinktrue">Clinical Pharmacology</a></li><li><a title="Indications &amp; Usage" href="#nlm34067-9" class="nlmlinktrue">Indications &amp; Usage</a></li><li><a title="Contraindications" href="#nlm34070-3" class="nlmlinktrue">Contraindications</a></li><li><a title="Warnings" href="#nlm43685-7" class="nlmlinktrue">Warnings</a></li><li><a title="Precautions" href="#nlm43685-7" class="nlmlinktrue">Precautions</a></li><li><a title="Adverse Reactions" href="#nlm34084-4" class="nlmlinktrue">Adverse Reactions</a></li><li><a title="Overdosage" href="#nlm34088-5" class="nlmlinktrue">Overdosage</a></li><li><a title="Dosage &amp; Administration" href="#nlm34068-7" class="nlmlinktrue">Dosage &amp; Administration</a></li><li><a title="How Supplied" href="#nlm34069-5" class="nlmlinktrue">How Supplied</a></li><li><a title="Patient Counseling Information" href="#nlm34076-0" class="nlmlinktrue">Patient Counseling Information</a></li><li><a title="Supplemental Patient Material" href="#nlm38056-8" class="nlmlinkfalse">Supplemental Patient Material</a></li><li><a title="Boxed Warning" href="#nlm34066-1" class="nlmlinkfalse">Boxed Warning</a></li><li><a title="Patient Package Insert" href="#nlm42230-3" class="nlmlinkfalse">Patient Package Insert</a></li><li><a title="Highlights" href="#nlmhighlights" class="nlmlinktrue">Highlights</a></li><li><a title="Full Table of Contents" href="javascript:nlmftoc('nlmftoc');" class="nlmlinktrue">Full Table of Contents</a></li><li><a href="#" class="nlmlinkfalse">Medication Guide</a></li></ul></div></fieldset></div>			<div class="spl">				<a name="druglabelcontent"></a><div id="nlmhighlightsmarker"><div class="Highlights" id="Highlights"><table border="0" style="table-layout:fixed" width="100%" cellpadding="5" cellspacing="5"><tr><td valign="top" align="left" width="50%"><div><a name="nlmhighlights"><h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1></a><div class="HighlightsDisclaimer">  These highlights do not include all the information needed to use letrozole tablets safely and effectively. See full prescribing information for letrozole tablets.<br>Letrozole tablets USP, 2.5 mg<br>Initial U.S. Approval: 1997<br></div><div class="HighlightSection"><h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1><div><p class="Highlighta">Adjuvant Treatment of Early Breast Cancer (1.1, 2.2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;04/2010 </p></div></div><div></div><div class="HighlightSection"><h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1><div><br>Letrozole tablet is an aromatase inhibitor indicated for:&nbsp;<ul class="Disc"><li>Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer (1.1)</li><li>Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy (1.2)</li><li>First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer (1.3)</li></ul></div><div></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1><div><br>Letrozole tablets are taken orally without regard to meals (2):<br><ul class="Disc"><li>Recommended dose:&nbsp;2.5 mg once daily (2.1)</li><li>Patients with cirrhosis or severe hepatic impairment: 2.5&nbsp;mg every other day (2.5, 5.3)</li></ul></div><div></div><div></div><div></div><div></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1><div><br>2.5 milligram tablets&nbsp;(3)</div></div><div class="HighlightSection"><h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1><div><br>Women of premenopausal endocrine status, including pregnant women (4)</div></div><div class="HighlightSection"><h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1><div><ul class="Disc"><li>Decreases in bone mineral density may occur. Consider bone mineral density monitoring&nbsp;(5.1)</li><li>Increases in total cholesterol may occur. Consider cholesterol monitoring. (5.2)</li><li>Fatigue, dizziness and somnolence may occur. Exercise caution when operating machinery (5.4)</li></ul></div><div></div><div></div><div></div><div></div><div></div></div><div class="HighlightSection"><h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1><div><br>The most common adverse reactions (&gt;20%) were hot flashes, arthralgia (6.1); flushing, asthenia, edema, arthralgia, headache, dizziness, hypercholesterolemia, sweating increased, bone pain (6.2, 6.3); and musculoskeletal (6.4).<br>&nbsp;<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or <span class="Underline"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span>.</span> </p></div><div></div><div></div><div></div><div></div><div></div><div></div><div></div></div><div></div><div><div></div><div></div><div></div></div><div></div><div></div><div><div></div><div></div><div></div></div><div><div></div><div></div></div><div><div></div><div></div><div></div><div></div><div></div></div><div></div><div></div><div></div><div></div><p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p><p class="HighlightsRevision">Revised: 6/2011</p></div></td></tr></table></div></div><div id="nlmftoc"><span id="backtodmsections"><a title=" Back to Highlights and Tabs " href="javascript:nlmftoc('backtodmsections');">Back to Highlights and Tabs</a></span><div class="Index" id="Index"><table style="table-layout:fixed" width="100%" cellpadding="5" cellspacing="5"><tr><td valign="top" align="left" width="50%"><div><h1 class="Colspan"><a style="text-decoration:none;" name="dmsections">FULL PRESCRIBING INFORMATION: CONTENTS</a><a name="footnote-reference-content" href="#footnote-content">*</a></h1><h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1><h2><a href="#section-1.1" class="toc">1.1 Adjuvant Treatment of Early Breast Cancer</a></h2><h2><a href="#section-1.2" class="toc">1.2 Extended Adjuvant Treatment of Early Breast Cancer</a></h2><h2><a href="#section-1.3" class="toc">1.3 First and Second-Line Treatment of Advanced Breast Cancer</a></h2><h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1><h2><a href="#section-2.1" class="toc">2.1 Recommended Dose</a></h2><h2><a href="#section-2.2" class="toc">2.2 Use in Adjuvant Treatment of Early Breast Cancer</a></h2><h2><a href="#section-2.3" class="toc">2.3 Use in Extended Adjuvant Treatment of   Early Breast Cancer</a></h2><h2><a href="#section-2.4" class="toc">2.4 Use in First and Second-Line Treatment of Advanced Breast Cancer</a></h2><h2><a href="#section-2.5" class="toc">2.5 Use in Hepatic Impairment</a></h2><h2><a href="#section-2.6" class="toc">2.6 Use in Renal Impairment</a></h2><h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1><h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1><h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1><h2><a href="#section-5.1" class="toc">5.1 Bone Effects</a></h2><h2><a href="#section-5.2" class="toc">5.2 Cholesterol</a></h2><h2><a href="#section-5.3" class="toc">5.3 Hepatic Impairment</a></h2><h2><a href="#section-5.4" class="toc">5.4 Fatigue and Dizziness</a></h2><h2><a href="#section-5.5" class="toc">5.5 Laboratory Test Abnormalities</a></h2><h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1><h2><a href="#section-6.1" class="toc">6.1 Adjuvant Treatment of Early Breast Cancer</a></h2><h2><a href="#section-6.2" class="toc">6.2 Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 24 Months</a></h2><h2><a href="#section-6.3" class="toc">6.3 Updated Analysis, Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 60 Months</a></h2><h2><a href="#section-6.4" class="toc">6.4 First-Line Treatment of Advanced Breast Cancer</a></h2><h2><a href="#section-6.5" class="toc">6.5 Second- Line Treatment of Advanced Breast Cancer</a></h2><h2><a href="#section-6.6" class="toc">6.6 First and Second-Line Treatment of Advanced Breast Cancer</a></h2><h2><a href="#section-6.7" class="toc">6.7 Postmarketing Experience</a></h2><h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1><h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1><h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2><h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2><h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2><h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2><h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1><h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1><h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1><h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2><h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2><h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2><h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1><h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis , Impairment Of Fertility</a></h2><h2><a href="#section-12.2" class="toc">13.2 Animal Pharmacology and/or Toxicology</a></h2><h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1><h2><a href="#section-13.1" class="toc">14.1 Updated Adjuvant Treatment of Early  Breast Cancer</a></h2><h2><a href="#section-13.2" class="toc">14.2 Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 24 Months</a></h2><h2><a href="#section-13.3" class="toc">14.3 Updated Analyses of Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 60 Months</a></h2><h2><a href="#section-13.4" class="toc">14.4 First-Line Treatment of Advanced Breast Cancer</a></h2><h2><a href="#section-13.5" class="toc">14.5 Second-Line Treatment of Advanced Breast Cancer</a></h2><h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1><h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1><dl class="Footnote"><dt><a name="footnote-content" href="#footnote-reference-content">*</a></dt><dd>Sections or subsections omitted from the full prescribing information are not listed.</dd></dl></div></td></tr></table></div></div><div class="Contents"><h1>FULL PRESCRIBING INFORMATION</h1><div class="Section"><a name="nlm48780-1"></a><a name="DLDE"></a><a name="section-1"></a><p></p></div><div class="Section"><a name="nlm34067-9"></a><a name="Section_1"></a><a name="section-1"></a><p></p><h1>1 INDICATIONS AND USAGE</h1><div class="Section"><a name="nlm42229-5"></a><a name="Section_1.1"></a><a name="section-1.1"></a><p></p><h2>1.1 Adjuvant Treatment of Early Breast Cancer</h2><br><p class="First">Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="Section_1.2"></a><a name="section-1.2"></a><p></p><h2>1.2 Extended Adjuvant Treatment of Early Breast Cancer</h2><br><p class="First">Letrozole tablets are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women,&nbsp;who have received 5 years of adjuvant tamoxifen therapy.&nbsp;The effectiveness of letrozole tablets in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole tablets for a median of 60 months <span class="Italics">[see <a href="#Section_14">Clinical Studies (14.2, 14.3)</a>]</span>.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="Section_1.4"></a><a name="section-1.3"></a><p></p><h2>1.3 First and Second-Line Treatment of Advanced Breast Cancer</h2><br>Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy&nbsp;<span class="Italics">[see <a href="#Section_14">Clinical Studies (14.4, 14.5)</a>]. </span></div></div><div class="Section"><a name="nlm34068-7"></a><a name="Section_2"></a><a name="section-2"></a><p></p><h1>2 DOSAGE AND ADMINISTRATION</h1><div class="Section"><a name="nlm42229-5"></a><a name="Section_2.1"></a><a name="section-2.1"></a><p></p><h2>2.1 Recommended Dose</h2><br><p class="First">The recommended dose of letrozole tablets is one 2.5 mg tablet administered once a day, without regard to meals.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="Section_2.2"></a><a name="section-2.2"></a><p></p><h2>2.2 Use in Adjuvant Treatment of Early Breast Cancer</h2><br>In the adjuvant setting, the optimal duration of treatment with letrozole is unknown. The planned duration of treatment in the study was 5 years with 73% of the patients having completed&nbsp;adjuvant therapy. Treatment should be discontinued at relapse&nbsp;<span class="Italics">[see <a href="#Section_14.1">Clinical Studies (14.1)</a>].</span></div><div class="Section"><a name="nlm42229-5"></a><a name="Section_2.3"></a><a name="section-2.3"></a><p></p><h2>2.3 Use in Extended Adjuvant Treatment of   Early Breast Cancer</h2><br>In the extended adjuvant setting, the optimal treatment duration with letrozole tablets is not known.&nbsp;The planned duration of treatment in the study was 5 years.&nbsp;In the final updated analysis,&nbsp;conducted at a median follow-up of 62 months, the median treatment duration was 60 months.&nbsp;Seventy-one percent of patients were treated for at least 3 years and 58% of patients completed at least 4.5 years of extended adjuvant treatment. The treatment should be discontinued at tumor relapse&nbsp;<span class="Italics">[see <a href="#Section_14.2">Clinical Studies (14.2 )</a>].</span></div><div class="Section"><a name="nlm42229-5"></a><a name="Section_2.4"></a><a name="section-2.4"></a><p></p><h2>2.4 Use in First and Second-Line Treatment of Advanced Breast Cancer</h2><br>In patients with advanced disease, treatment with letrozole tablets should continue until tumor progression is evident.&nbsp;<span class="Italics">[see <a href="#Section_14">Clinical Studies (14.4, 14.5)</a>]</span></div><div class="Section"><a name="nlm42229-5"></a><a name="Section_2.5"></a><a name="section-2.5"></a><p></p><h2>2.5 Use in Hepatic Impairment</h2><br>No dosage adjustment is recommended for patients with mild to moderate hepatic impairment, although letrozole tablets blood concentrations were modestly increased in subjects with moderate hepatic impairment due to cirrhosis. The dose of letrozole tablets in patients with cirrhosis and severe hepatic dysfunction should be reduced by 50% <span class="Italics">[see&nbsp;<a href="#Section_5.3">Warnings and Precautions (5.3)</a>].</span> The recommended dose of letrozole tablets for such patients is 2.5 mg administered every other day. The effect of hepatic impairment on letrozole tablets exposure in noncirrhotic cancer patients with elevated bilirubin levels has not been determined.</div><div class="Section"><a name="nlm42229-5"></a><a name="Section_2.6"></a><a name="section-2.6"></a><p></p><h2>2.6 Use in Renal Impairment</h2><br>No dosage adjustment is required for patients with renal impairment if creatinine clearance is &ge;10 mL/min. <span class="Italics">[see <a href="#Section_12.3">Clinical Pharmacology&nbsp;(12.3)</a>]</span>.</div></div><div class="Section"><a name="nlm43678-2"></a><a name="Section_3"></a><a name="section-3"></a><p></p><h1>3 DOSAGE FORMS AND STRENGTHS</h1><br>2.5 mg tablets: Yellow colored, film-coated, round shaped tablets debossed with one side 'N' and other side 'L'.</div><div class="Section"><a name="nlm34070-3"></a><a name="Section_4"></a><a name="section-4"></a><p></p><h1>4 CONTRAINDICATIONS</h1><br>Letrozole tablets&nbsp;may cause fetal harm when administered to a pregnant woman&nbsp;and&nbsp;the clinical benefit to premenopausal women with breast cancer has not been demonstrated. Letrozole tablets are contraindicated in women who are or may become pregnant.&nbsp;If letrozole tablets are used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. <span class="Italics">[see <a href="#Section_8.1">Use in Specific Populations (8.1)</a>]</span></div><div class="Section"><a name="nlm43685-7"></a><a name="Section_5"></a><a name="section-5"></a><p></p><h1>5 WARNINGS AND PRECAUTIONS</h1><div class="Section"><a name="nlm42229-5"></a><a name="Section_5.1"></a><a name="section-5.1"></a><p></p><h2>5.1 Bone Effects</h2><br>Use of letrozole tablets may cause decreases in bone mineral density (BMD). Consideration should be given to monitoring BMD. Results of a substudy to evaluate safety in the adjuvant setting comparing the effect on lumbar spine (L2-L4) bone mineral density (BMD) of adjuvant treatment with letrozole to that with tamoxifen showed at 24 months a median decrease in lumbar spine BMD of 4.1% in the letrozole arm compared to a median increase of 0.3% in the tamoxifen arm (difference = 4.4%) (<span class="Italics">P</span>&lt;0.0001) [<span class="Italics">see <a href="#Section_6.1">Adverse Reactions (6.1)</a></span>].&nbsp;Updated results from the BMD&nbsp;sub-study in the extended adjuvant setting demonstrated that at 2 years patients receiving letrozole&nbsp;had a median decrease from baseline of 3.8% in hip BMD compared to a median decrease of 2.0% in the placebo group.&nbsp;The changes from baseline in lumbar spine BMD in letrozole and placebo treated groups were not significantly different&nbsp;<span class="Italics">[see&nbsp;<a href="#Section_6.2">Adverse Reactions (6.2)</a>].</span><br><span class="Italics"></span>&nbsp;<br>In the adjuvant trial the incidence of bone fractures at any time after randomization was 13.8% for letrozole and 10.5% for tamoxifen. The incidence of osteoporosis&nbsp;was 5.1% for letrozole and 2.7% for tamoxifen [<span class="Italics">See <a href="#Section_6.1">Adverse Reactions (6.1)</a></span>].&nbsp;In the extended adjuvant trial the incidence of bone fractures at any time after randomization was 13.3% for letrozole and 7.8% for placebo.&nbsp;The incidence of new osteoporosis was 14.5% for letrozole and 7.8% for placebo <span class="Italics">[see <a href="#Section_6.3">Adverse Reactions (6.3)</a>].</span></div><div class="Section"><a name="nlm42229-5"></a><a name="Section_5.2"></a><a name="section-5.2"></a><p></p><h2>5.2 Cholesterol</h2><br>Consideration should be given to monitoring serum cholesterol. In the adjuvant trial hypercholesterolemia was reported in 52.3% of letrozole patients and 28.6% of tamoxifen patients.&nbsp;CTC grade 3-4 hypercholesterolemia was reported in 0.4% of letrozole patients and 0.1% of tamoxifen patients.&nbsp;Also in the&nbsp;adjuvant setting, an increase of &ge;1.5 X ULN in total cholesterol (generally non-fasting) was observed in patients on monotherapy who had baseline total serum cholesterol within the normal range&nbsp;(i.e., &lt;=1.5 X ULN) in 151/1843 (8.2%) on letrozole vs 57/1840&nbsp;(3.2%).&nbsp;Lipid lowering medications were required for 25% of patients on&nbsp;letrozole and 16% on tamoxifen <span class="Italics">[see&nbsp;<a href="#Section_6.2">Adverse Reactions (6.2)</a>].&nbsp;</span></div><div class="Section"><a name="nlm42229-5"></a><a name="Section_5.3"></a><a name="section-5.3"></a><p></p><h2>5.3 Hepatic Impairment</h2><br>Subjects with cirrhosis and severe hepatic impairment who were dosed with 2.5 mg of letrozole tablets experienced approximately twice the exposure to letrozole tablets as healthy volunteers with normal liver function. Therefore, a dose reduction is recommended for&nbsp;this&nbsp;patient&nbsp;population.&nbsp;The effect of hepatic impairment on letrozole tablets exposure in cancer patients with elevated bilirubin levels has not been determined. <span class="Italics">[see <a href="#Section_2.5">Dosage and Administration (2.5)</a>]</span></div><div class="Section"><a name="nlm42229-5"></a><a name="Section_5.4"></a><a name="section-5.4"></a><p></p><h2>5.4 Fatigue and Dizziness</h2><br>Because fatigue, dizziness, and somnolence have been reported with the use of letrozole tablets, caution is advised when driving or using machinery until it is known how the patient reacts to letrozole tablets use.</div><div class="Section"><a name="nlm42229-5"></a><a name="Section_5.5"></a><a name="section-5.5"></a><p></p><h2>5.5 Laboratory Test Abnormalities</h2><br>No dose-related effect of letrozole tablets on any hematologic or clinical chemistry parameter was evident. Moderate decreases in lymphocyte counts, of uncertain clinical significance, were observed in some patients receiving letrozole tablets 2.5 mg. This depression was transient in about half of those affected. Two patients on letrozole tablets developed thrombocytopenia; relationship to the study drug was unclear. Patient withdrawal due to laboratory abnormalities, whether related to study treatment or not, was infrequent.</div></div><div class="Section"><a name="nlm34084-4"></a><a name="Section_6"></a><a name="section-6"></a><p></p><h1>6 ADVERSE REACTIONS</h1><br>The most serious adverse reactions from the use of letrozole tablets are:<br><ul class="Disc"><li>Bone effects <span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions (5.1)</a>]</span></li><li>Increases in cholesterol&nbsp;<span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>]</span></li></ul><p class="First">Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><div class="Section"><a name="nlm42229-5"></a><a name="Section_6.1"></a><a name="section-6.1"></a><p></p><h2>6.1 Adjuvant Treatment of Early Breast Cancer</h2><br>The median treatment duration of adjuvant treatment was 60 months and the median duration of follow-up for safety was 73 months for patients receiving letrozole tablets&nbsp;and tamoxifen.<br>&nbsp;<br>Certain adverse reactions were prospectively specified for analysis, based on the known pharmacologic properties and side effect profiles of the two drugs.<br>&nbsp;<br>Adverse reactions were analyzed irrespective of whether a symptom was present or absent at baseline. Most adverse reactions reported (approximately 75% of patients reporting 1 or more AE) were Grade 1 or Grade 2 applying the Common Toxicity Criteria Version 2.0/ Common Terminology Criteria for Adverse Events, version 3.0.&nbsp;Table 1 describes adverse reactions (Grades 1-4) irrespective of relationship to study treatment in the adjuvant trial for the monotherapy arms analysis (safety population).<br><p class="First"><span class="Bold">Table 1: Patients with Adverse Reactions (CTC Grades 1-4, Irrespective of Relationship to Study Drug)&nbsp;in the Adjuvant Study &ndash; Monotherapy Arms Analysis </span><span class="Bold">(Median Follow-up 73 Months; Median Treatment 60 Months)</span></p><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="Botrule First"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" align="center" colspan="4" valign="top"><span class="Bold">Grades 1-4</span><br></td><td class="Rrule" align="center" colspan="4" valign="top"><span class="Bold">Grades 3-4</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">Adverse Reaction</span><br></td><td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">Letrozole tablets</span><span class="Bold"><br>N=2448<br>n (%)</span><br></td><td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">tamoxifen</span><br><span class="Bold">N=2447</span><br><span class="Bold">n (%)</span><br></td><td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">Letrozole tablets</span><br><span class="Bold">N=2448</span><br><span class="Bold">n (%)</span><br></td><td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">tamoxifen</span><br><span class="Bold">N=2447</span><br><span class="Bold">n (%)</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Pts with any adverse event<br></td><td class="Rrule" align="center" valign="top">2310<br></td><td class="Rrule" align="center" valign="top">(94.4)<br></td><td class="Rrule" align="center" valign="top">2214<br></td><td class="Rrule" align="center" valign="top">(90.5)<br></td><td class="Rrule" align="center" valign="top">635<br></td><td class="Rrule" align="center" valign="top">(25.9)<br></td><td class="Rrule" align="center" valign="top">604<br></td><td class="Rrule" align="center" valign="top">(24.7)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Hypercholesterolemia<br></td><td class="Rrule" align="center" valign="top">1280<br></td><td class="Rrule" align="center" valign="top">(52.3)<br></td><td class="Rrule" align="center" valign="top">700<br></td><td class="Rrule" align="center" valign="top">(28.6)<br></td><td class="Rrule" align="center" valign="top">11<br></td><td class="Rrule" align="center" valign="top">( 0.4)<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">( 0.2)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Hot Flashes/Flushes<br></td><td class="Rrule" align="center" valign="top">821<br></td><td class="Rrule" align="center" valign="top">(33.5)<br></td><td class="Rrule" align="center" valign="top">929<br></td><td class="Rrule" align="center" valign="top">(38.0)<br></td><td class="Rrule" align="center" valign="top">0<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">0<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Arthralgia/Arthritis<br></td><td class="Rrule" align="center" valign="top">618<br></td><td class="Rrule" align="center" valign="top">(25.2)<br></td><td class="Rrule" align="center" valign="top">501<br></td><td class="Rrule" align="center" valign="top">(20.4)<br></td><td class="Rrule" align="center" valign="top">85<br></td><td class="Rrule" align="center" valign="top">( 3.5)<br></td><td class="Rrule" align="center" valign="top">50<br></td><td class="Rrule" align="center" valign="top">( 2.0)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Night Sweats<br></td><td class="Rrule" align="center" valign="top">357<br></td><td class="Rrule" align="center" valign="top">(14.6)<br></td><td class="Rrule" align="center" valign="top">426<br></td><td class="Rrule" align="center" valign="top">(17.4)<br></td><td class="Rrule" align="center" valign="top">0<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">0<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Bone Fractures<span class="Sup">2</span><br></td><td class="Rrule" align="center" valign="top">338<br></td><td class="Rrule" align="center" valign="top">(13.8)<br></td><td class="Rrule" align="center" valign="top">257<br></td><td class="Rrule" align="center" valign="top">(10.5)<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Weight Increase<br></td><td class="Rrule" align="center" valign="top">317<br></td><td class="Rrule" align="center" valign="top">(12.9)<br></td><td class="Rrule" align="center" valign="top">378<br></td><td class="Rrule" align="center" valign="top">(15.4)<br></td><td class="Rrule" align="center" valign="top">27<br></td><td class="Rrule" align="center" valign="top">( 1.1)<br></td><td class="Rrule" align="center" valign="top">39<br></td><td class="Rrule" align="center" valign="top">( 1.6)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Nausea<br></td><td class="Rrule" align="center" valign="top">283<br></td><td class="Rrule" align="center" valign="top">(11.6)<br></td><td class="Rrule" align="center" valign="top">277<br></td><td class="Rrule" align="center" valign="top">(11.3)<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">( 0.2)<br></td><td class="Rrule" align="center" valign="top">9<br></td><td class="Rrule" align="center" valign="top">( 0.4)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Bone Fractures<span class="Sup">1</span><br></td><td class="Rrule" align="center" valign="top">247<br></td><td class="Rrule" align="center" valign="top">(10.1)<br></td><td class="Rrule" align="center" valign="top">174<br></td><td class="Rrule" align="center" valign="top">( 7.1)<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Fatigue (Lethargy, Malaise, Asthenia)<br></td><td class="Rrule" align="center" valign="top">235<br></td><td class="Rrule" align="center" valign="top">(9.6)<br></td><td class="Rrule" align="center" valign="top">250<br></td><td class="Rrule" align="center" valign="top">(10.2)<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">( 0.2)<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">( 0.3)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Myalgia<br></td><td class="Rrule" align="center" valign="top">217<br></td><td class="Rrule" align="center" valign="top">( 8.9)<br></td><td class="Rrule" align="center" valign="top">212<br></td><td class="Rrule" align="center" valign="top">( 8.7)<br></td><td class="Rrule" align="center" valign="top">18<br></td><td class="Rrule" align="center" valign="top">( 0.7)<br></td><td class="Rrule" align="center" valign="top">14<br></td><td class="Rrule" align="center" valign="top">( 0.6)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Edema<br></td><td class="Rrule" align="center" valign="top">164<br></td><td class="Rrule" align="center" valign="top">( 6.7)<br></td><td class="Rrule" align="center" valign="top">160<br></td><td class="Rrule" align="center" valign="top">( 6.5)<br></td><td class="Rrule" align="center" valign="top">3<br></td><td class="Rrule" align="center" valign="top">( 0.1)<br></td><td class="Rrule" align="center" valign="top">1<br></td><td class="Rrule" align="center" valign="top">(&lt;0.1)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Weight Decrease<br></td><td class="Rrule" align="center" valign="top">140<br></td><td class="Rrule" align="center" valign="top">( 5.7)<br></td><td class="Rrule" align="center" valign="top">129<br></td><td class="Rrule" align="center" valign="top">( 5.3)<br></td><td class="Rrule" align="center" valign="top">8<br></td><td class="Rrule" align="center" valign="top">( 0.3)<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">( 0.2)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Vaginal Bleeding<br></td><td class="Rrule" align="center" valign="top">128<br></td><td class="Rrule" align="center" valign="top">( 5.2)<br></td><td class="Rrule" align="center" valign="top">320<br></td><td class="Rrule" align="center" valign="top">(13.1)<br></td><td class="Rrule" align="center" valign="top">1<br></td><td class="Rrule" align="center" valign="top">(&lt;0.1)<br></td><td class="Rrule" align="center" valign="top">8<br></td><td class="Rrule" align="center" valign="top">( 0.3)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Back Pain<br></td><td class="Rrule" align="center" valign="top">125<br></td><td class="Rrule" align="center" valign="top">( 5.1)<br></td><td class="Rrule" align="center" valign="top">136<br></td><td class="Rrule" align="center" valign="top">( 5.6)<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">( 0.3)<br></td><td class="Rrule" align="center" valign="top">11<br></td><td class="Rrule" align="center" valign="top">( 0.4)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Osteoporosis NOS<br></td><td class="Rrule" align="center" valign="top">124<br></td><td class="Rrule" align="center" valign="top">( 5.1)<br></td><td class="Rrule" align="center" valign="top">66<br></td><td class="Rrule" align="center" valign="top">( 2.7)<br></td><td class="Rrule" align="center" valign="top">10<br></td><td class="Rrule" align="center" valign="top">( 0.4)<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">( 0.2)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Bone pain<br></td><td class="Rrule" align="center" valign="top">123<br></td><td class="Rrule" align="center" valign="top">( 5.0)<br></td><td class="Rrule" align="center" valign="top">109<br></td><td class="Rrule" align="center" valign="top">( 4.5)<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">( 0.2)<br></td><td class="Rrule" align="center" valign="top">4<br></td><td class="Rrule" align="center" valign="top">( 0.2)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Depression<br></td><td class="Rrule" align="center" valign="top">119<br></td><td class="Rrule" align="center" valign="top">( 4.9)<br></td><td class="Rrule" align="center" valign="top">114<br></td><td class="Rrule" align="center" valign="top">( 4.7)<br></td><td class="Rrule" align="center" valign="top">16<br></td><td class="Rrule" align="center" valign="top">( 0.7)<br></td><td class="Rrule" align="center" valign="top">14<br></td><td class="Rrule" align="center" valign="top">( 0.6)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Vaginal Irritation<br></td><td class="Rrule" align="center" valign="top">111<br></td><td class="Rrule" align="center" valign="top">( 4.5)<br></td><td class="Rrule" align="center" valign="top">77<br></td><td class="Rrule" align="center" valign="top">( 3.1)<br></td><td class="Rrule" align="center" valign="top">2<br></td><td class="Rrule" align="center" valign="top">(&lt;0.1)<br></td><td class="Rrule" align="center" valign="top">2<br></td><td class="Rrule" align="center" valign="top">(&lt;0.1)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Headache<br></td><td class="Rrule" align="center" valign="top">105<br></td><td class="Rrule" align="center" valign="top">( 4.3)<br></td><td class="Rrule" align="center" valign="top">94<br></td><td class="Rrule" align="center" valign="top">( 3.8)<br></td><td class="Rrule" align="center" valign="top">9<br></td><td class="Rrule" align="center" valign="top">( 0.4)<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">( 0.2)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Pain in extremity<br></td><td class="Rrule" align="center" valign="top">103<br></td><td class="Rrule" align="center" valign="top">( 4.2)<br></td><td class="Rrule" align="center" valign="top">79<br></td><td class="Rrule" align="center" valign="top">( 3.2)<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">( 0.2)<br></td><td class="Rrule" align="center" valign="top">4<br></td><td class="Rrule" align="center" valign="top">( 0.2)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Osteopenia<br></td><td class="Rrule" align="center" valign="top">87<br></td><td class="Rrule" align="center" valign="top">( 3.6)<br></td><td class="Rrule" align="center" valign="top">74<br></td><td class="Rrule" align="center" valign="top">( 3.0)<br></td><td class="Rrule" align="center" valign="top">0<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">2<br></td><td class="Rrule" align="center" valign="top">(&lt;0.1)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Dizziness/Light-Headedness<br></td><td class="Rrule" align="center" valign="top">84<br></td><td class="Rrule" align="center" valign="top">( 3.4)<br></td><td class="Rrule" align="center" valign="top">84<br></td><td class="Rrule" align="center" valign="top">( 3.4)<br></td><td class="Rrule" align="center" valign="top">1<br></td><td class="Rrule" align="center" valign="top">(&lt;0.1)<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">(0.2)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Alopecia<br></td><td class="Rrule" align="center" valign="top">83<br></td><td class="Rrule" align="center" valign="top">( 3.4)<br></td><td class="Rrule" align="center" valign="top">84<br></td><td class="Rrule" align="center" valign="top">( 3.4)<br></td><td class="Rrule" align="center" valign="top">0<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">0<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Vomiting<br></td><td class="Rrule" align="center" valign="top">80<br></td><td class="Rrule" align="center" valign="top">( 3.3)<br></td><td class="Rrule" align="center" valign="top">80<br></td><td class="Rrule" align="center" valign="top">( 3.3)<br></td><td class="Rrule" align="center" valign="top">3<br></td><td class="Rrule" align="center" valign="top">( 0.1)<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">(0.2)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Cataract<br></td><td class="Rrule" align="center" valign="top">49<br></td><td class="Rrule" align="center" valign="top">( 2.0)<br></td><td class="Rrule" align="center" valign="top">54<br></td><td class="Rrule" align="center" valign="top">( 2.2)<br></td><td class="Rrule" align="center" valign="top">16<br></td><td class="Rrule" align="center" valign="top">( 0.7)<br></td><td class="Rrule" align="center" valign="top">17<br></td><td class="Rrule" align="center" valign="top">( 0.7)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Constipation<br></td><td class="Rrule" align="center" valign="top">49<br></td><td class="Rrule" align="center" valign="top">( 2.0)<br></td><td class="Rrule" align="center" valign="top">71<br></td><td class="Rrule" align="center" valign="top">( 2.9)<br></td><td class="Rrule" align="center" valign="top">3<br></td><td class="Rrule" align="center" valign="top">( 0.1)<br></td><td class="Rrule" align="center" valign="top">1<br></td><td class="Rrule" align="center" valign="top">(&lt;0.1)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Breast pain<br></td><td class="Rrule" align="center" valign="top">37<br></td><td class="Rrule" align="center" valign="top">( 1.5)<br></td><td class="Rrule" align="center" valign="top">43<br></td><td class="Rrule" align="center" valign="top">( 1.8)<br></td><td class="Rrule" align="center" valign="top">1<br></td><td class="Rrule" align="center" valign="top">(&lt;0.1)<br></td><td class="Rrule" align="center" valign="top">0<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Anorexia<br></td><td class="Rrule" align="center" valign="top">20<br></td><td class="Rrule" align="center" valign="top">( 0.8)<br></td><td class="Rrule" align="center" valign="top">20<br></td><td class="Rrule" align="center" valign="top">( 0.8)<br></td><td class="Rrule" align="center" valign="top">1<br></td><td class="Rrule" align="center" valign="top">(&lt;0.1)<br></td><td class="Rrule" align="center" valign="top">1<br></td><td class="Rrule" align="center" valign="top">(&lt;0.1)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Endometrial Hyperplasia/ Cancer<span class="Sup">2, 3</span><br></td><td class="Rrule" align="center" valign="top">11/1909<br></td><td class="Rrule" align="center" valign="top">( 0.6)<br></td><td class="Rrule" align="center" valign="top">70/1943<br></td><td class="Rrule" align="center" valign="top">( 3.6)<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Endometrial Proliferation Disorders<br></td><td class="Rrule" align="center" valign="top">10<br></td><td class="Rrule" align="center" valign="top">(0.3)<br></td><td class="Rrule" align="center" valign="top">71<br></td><td class="Rrule" align="center" valign="top">(1.8)<br></td><td class="Rrule" align="center" valign="top">0<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">14<br></td><td class="Rrule" align="center" valign="top">(0.6)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Endometrial Hyperplasia/ Cancer<span class="Sup">1, 3</span><br></td><td class="Rrule" align="center" valign="top">6/1909<br></td><td class="Rrule" align="center" valign="top">( 0.3)<br></td><td class="Rrule" align="center" valign="top">57/1943<br></td><td class="Rrule" align="center" valign="top">(2.9)<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Other Endometrial Disorders<br></td><td class="Rrule" align="center" valign="top">2<br></td><td class="Rrule" align="center" valign="top">(&lt;0.1)<br></td><td class="Rrule" align="center" valign="top">3<br></td><td class="Rrule" align="center" valign="top">( 0.1)<br></td><td class="Rrule" align="center" valign="top">0<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">0<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Myocardial Infarction<span class="Sup">1</span><br></td><td class="Rrule" align="center" valign="top">24<br></td><td class="Rrule" align="center" valign="top">( 1.0)<br></td><td class="Rrule" align="center" valign="top">12<br></td><td class="Rrule" align="center" valign="top">( 0.5)<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Myocardial Infarction<span class="Sup">2</span><br></td><td class="Rrule" align="center" valign="top">37<br></td><td class="Rrule" align="center" valign="top">( 1.5)<br></td><td class="Rrule" align="center" valign="top">25<br></td><td class="Rrule" align="center" valign="top">(1.0)<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Myocardial Ischemia<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">( 0.2)<br></td><td class="Rrule" align="center" valign="top">9<br></td><td class="Rrule" align="center" valign="top">( 0.4)<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Cerebrovascular Accident<span class="Sup">1</span><br></td><td class="Rrule" align="center" valign="top">52<br></td><td class="Rrule" align="center" valign="top">( 2.1)<br></td><td class="Rrule" align="center" valign="top">46<br></td><td class="Rrule" align="center" valign="top">( 1.9)<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Cerebrovascular Accident<span class="Sup">2</span><br></td><td class="Rrule" align="center" valign="top">70<br></td><td class="Rrule" align="center" valign="top">( 2.9)<br></td><td class="Rrule" align="center" valign="top">63<br></td><td class="Rrule" align="center" valign="top">( 2.6)<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Angina<span class="Sup">1</span><br></td><td class="Rrule" align="center" valign="top">26<br></td><td class="Rrule" align="center" valign="top">( 1.1)<br></td><td class="Rrule" align="center" valign="top">24<br></td><td class="Rrule" align="center" valign="top">( 1.0)<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Angina<span class="Sup">2</span><br></td><td class="Rrule" align="center" valign="top">32<br></td><td class="Rrule" align="center" valign="top">( 1.3)<br></td><td class="Rrule" align="center" valign="top">31<br></td><td class="Rrule" align="center" valign="top">( 1.3)<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Thromboembolic Event<span class="Sup">1</span><br></td><td class="Rrule" align="center" valign="top">51<br></td><td class="Rrule" align="center" valign="top">( 2.1)<br></td><td class="Rrule" align="center" valign="top">89<br></td><td class="Rrule" align="center" valign="top">( 3.6)<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Thromboembolic Event<span class="Sup">2</span><br></td><td class="Rrule" align="center" valign="top">71<br></td><td class="Rrule" align="center" valign="top">( 2.9)<br></td><td class="Rrule" align="center" valign="top">111<br></td><td class="Rrule" align="center" valign="top">( 4.5)<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Other Cardiovascular<span class="Sup">1</span><br></td><td class="Rrule" align="center" valign="top">260<br></td><td class="Rrule" align="center" valign="top">(10.6)<br></td><td class="Rrule" align="center" valign="top">256<br></td><td class="Rrule" align="center" valign="top">(10.5)<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Other Cardiovascular<span class="Sup">2</span><br></td><td class="Rrule" align="center" valign="top">312<br></td><td class="Rrule" align="center" valign="top">(12.7)<br></td><td class="Rrule" align="center" valign="top">337<br></td><td class="Rrule" align="center" valign="top">(13.8)<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">Second Malignancies<span class="Sup">1</span><br></td><td class="Rrule" align="center" valign="top">53<br></td><td class="Rrule" align="center" valign="top">( 2.2)<br></td><td class="Rrule" align="center" valign="top">78<br></td><td class="Rrule" align="center" valign="top">( 3.2)<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr><tr class="Last"><td class="Lrule Rrule" valign="top">Second Malignancies<span class="Sup">2</span><br></td><td class="Rrule" align="center" valign="top">102<br></td><td class="Rrule" align="center" valign="top">( 4.2)<br></td><td class="Rrule" align="center" valign="top">119<br></td><td class="Rrule" align="center" valign="top">( 4.9)<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">-<br></td></tr></tbody></table><br><p><span class="Sup">1&nbsp;</span>During study treatment, based on Safety Monotherapy population</p><p><span class="Sup">2</span>&nbsp;Any time after randomization, including post treatment follow-up</p><p><span class="Sup">3</span>&nbsp;Excluding women who had undergone hysterectomy before study entry</p><br>Note: Cardiovascular (including cerebrovascular and thromboembolic), skeletal and urogenital/endometrial events and second malignancies were collected life-long. All of these events were assumed to be of CTC grade 3-5 and were not individually graded.<br>&nbsp;<br>When considering all grades during study treatment, a higher incidence of events was&nbsp;seen for letrozole tablets regarding fractures (10.1% vs 7.1%), myocardial infarctions (1.0% vs 0.5%), and arthralgia (25.2% vs 20.4%) (letrozole tablets vs tamoxifen respectively).&nbsp;A higher incidence was seen for tamoxifen regarding thromboembolic events (2.1% vs 3.6%), endometrial hyperplasia/cancer (0.3% vs 2.9%), and endometrial proliferation disorders (0.3% vs 1.8%) (letrozole tablets vs tamoxifen respectively).<br><br>At a median follow up of 73 months, a higher incidence of events was seen for letrozole tablets (13.8%) than for tamoxifen (10.5%) regarding fractures. A higher incidence was seen for tamoxifen compared to letrozole tablets regarding thromboembolic events (4.5% vs 2.9%), and endometrial hyperplasia or cancer (2.9% vs 0.4%) (tamoxifen vs letrozole tablets, respectively).<br>&nbsp;<br>Bone Study: Results of a phase 3 safety trial in 262 post menopausal women with resected receptor positive early breast cancer in the adjuvant setting comparing the effect on lumbar spine (L2-L4) bone mineral density (BMD) of adjuvant treatment with letrozole to that with tamoxifen showed at 24 months a median decrease in lumbar spine BMD of 4.1% in the letrozole arm compared to a median increase of 0.3% in the tamoxifen arm (difference = 4.4%) (<span class="Italics">P</span>&lt;0.0001). No patients with a normal BMD at baseline became osteoporotic over the 2 years and only 1 patient with osteopenia at baseline (T score of -1.9) developed osteoporosis during the treatment period (assessment by central review). The results for total hip BMD were similar, although the differences between the two treatments were less pronounced. During the 2 year period, fractures were reported by 4 of 103 patients (4%) in the letrozole arm, and 6 of 97 patients (6%) in the tamoxifen arm.<br>&nbsp;<br>Lipid&nbsp;Study: In a phase 3 safety trial in 262 post menopausal women with resected receptor positive early breast cancer at 24 months comparing the effects on lipid profiles of adjuvant letrozole to tamoxifen, 12% of patients on letrozole had at least one total cholesterol value of a higher CTCAE grade than at baseline compared with 4% of patients on tamoxifen.</div><div class="Section"><a name="nlm42229-5"></a><a name="Section_6.2"></a><a name="section-6.2"></a><p></p><h2>6.2 Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 24 Months</h2><br>The median duration of extended adjuvant treatment was 24&nbsp;months and the median duration of follow-up for safety was 28 months for patients receiving letrozole tablets&nbsp;and placebo.<br>&nbsp;<br>Table 2 describes the adverse reactions occurring at a frequency of at least 5% in any treatment group during treatment.&nbsp;Most adverse reactions reported were Grade 1 and Grade 2 based on the Common Toxicity Criteria Version 2.0.&nbsp;In the extended adjuvant setting, the reported drug-related adverse reactions that were significantly different from placebo were hot flashes, arthralgia/arthritis, and myalgia.<br>&nbsp;<br><span class="Bold">Table 2: Percentage of Patients with Adverse Reactions</span><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="Botrule First"><td class="Lrule Rrule" colspan="2" valign="top">&nbsp; <br></td><td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">Number (%) of Patients with Grade 1-4 Adverse Reaction</span><br></td><td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">Number (%) of Patients with Grade 3-4 Adverse Reaction</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top"><span class="Bold">Letrozole tablets</span><br><span class="Bold">N=2563</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">Placebo</span><br><span class="Bold">N=2573</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">Letrozole tablets</span><br><span class="Bold">N=2563</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">Placebo</span><br><span class="Bold">N=2573</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Any Adverse Reaction</span><br></td><td class="Rrule" align="center" valign="top">2232 (87.1)<br></td><td class="Rrule" align="center" valign="top">2174 (84.5)<br></td><td class="Rrule" align="center" valign="top">419 (16.3)<br></td><td class="Rrule" align="center" valign="top">389 (15.1)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Vascular Disorders</span><br></td><td class="Rrule" align="center" valign="top">1375 (53.6)<br></td><td class="Rrule" align="center" valign="top">1230 (47.8)<br></td><td class="Rrule" align="center" valign="top">59 (2.3)<br></td><td class="Rrule" align="center" valign="top">74 (2.9)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Flushing <br></td><td class="Rrule" align="center" valign="top">1273 (49.7)<br></td><td class="Rrule" align="center" valign="top">1114 (43.3)<br></td><td class="Rrule" align="center" valign="top">3 (0.1)<br></td><td class="Rrule" align="center" valign="top">0 -<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">General Disorders </span><br></td><td class="Rrule" align="center" valign="top">1154 (45)<br></td><td class="Rrule" align="center" valign="top">1090 (42.4)<br></td><td class="Rrule" align="center" valign="top">30 (1.2)<br></td><td class="Rrule" align="center" valign="top">28 (1.1)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Asthenia<br></td><td class="Rrule" align="center" valign="top">862 (33.6)<br></td><td class="Rrule" align="center" valign="top">826 (32.1)<br></td><td class="Rrule" align="center" valign="top">16 (0.6)<br></td><td class="Rrule" align="center" valign="top">7 (0.3)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Edema NOS<br></td><td class="Rrule" align="center" valign="top">471 (18.4)<br></td><td class="Rrule" align="center" valign="top">416 (16.2)<br></td><td class="Rrule" align="center" valign="top">4 (0.2)<br></td><td class="Rrule" align="center" valign="top">3 (0.1)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Musculoskeletal Disorders</span><br></td><td class="Rrule" align="center" valign="top">978 (38.2)<br></td><td class="Rrule" align="center" valign="top">836 (32.5)<br></td><td class="Rrule" align="center" valign="top">71 (2.8)<br></td><td class="Rrule" align="center" valign="top">50 (1.9)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Arthralgia<br></td><td class="Rrule" align="center" valign="top">565 (22)<br></td><td class="Rrule" align="center" valign="top">465 (18.1)<br></td><td class="Rrule" align="center" valign="top">25 (1)<br></td><td class="Rrule" align="center" valign="top">20 (0.8)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Arthritis NOS<br></td><td class="Rrule" align="center" valign="top">173&nbsp;(6.7)<br></td><td class="Rrule" align="center" valign="top">124&nbsp;(4.8)<br></td><td class="Rrule" align="center" valign="top">10 (0.4)<br></td><td class="Rrule" align="center" valign="top">5 (0.2)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Myalgia<br></td><td class="Rrule" align="center" valign="top">171&nbsp;(6.7)<br></td><td class="Rrule" align="center" valign="top">122&nbsp;(4.7)<br></td><td class="Rrule" align="center" valign="top">8 (0.3)<br></td><td class="Rrule" align="center" valign="top">6 (0.2)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Back Pain<br></td><td class="Rrule" align="center" valign="top">129&nbsp;(5)<br></td><td class="Rrule" align="center" valign="top">112&nbsp;(4.4)<br></td><td class="Rrule" align="center" valign="top">8 (0.3)<br></td><td class="Rrule" align="center" valign="top">7 (0.3)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Nervous System Disorders</span><br></td><td class="Rrule" align="center" valign="top">863 (33.7)<br></td><td class="Rrule" align="center" valign="top">819 (31.8)<br></td><td class="Rrule" align="center" valign="top">65 (2.5)<br></td><td class="Rrule" align="center" valign="top">58 (2.3)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Headache<br></td><td class="Rrule" align="center" valign="top">516 (20.1)<br></td><td class="Rrule" align="center" valign="top">508 (19.7)<br></td><td class="Rrule" align="center" valign="top">18 (0.7)<br></td><td class="Rrule" align="center" valign="top">17 (0.7)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Dizziness<br></td><td class="Rrule" align="center" valign="top">363 (14.2)<br></td><td class="Rrule" align="center" valign="top">342 (13.3)<br></td><td class="Rrule" align="center" valign="top">9 (0.4)<br></td><td class="Rrule" align="center" valign="top">6 (0.2)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Skin Disorders</span><br></td><td class="Rrule" align="center" valign="top">830 (32.4)<br></td><td class="Rrule" align="center" valign="top">787 (30.6)<br></td><td class="Rrule" align="center" valign="top">17 (0.7)<br></td><td class="Rrule" align="center" valign="top">16 (0.6)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Sweating Increased<br></td><td class="Rrule" align="center" valign="top">619 (24.2)<br></td><td class="Rrule" align="center" valign="top">577 (22.4)<br></td><td class="Rrule" align="center" valign="top">1 (&lt;0.1)<br></td><td class="Rrule" align="center" valign="top">0 -<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Gastrointestinal Disorders</span><br></td><td class="Rrule" align="center" valign="top">725 (28.3)<br></td><td class="Rrule" align="center" valign="top">731 (28.4)<br></td><td class="Rrule" align="center" valign="top">43 (1.7)<br></td><td class="Rrule" align="center" valign="top">42 (1.6)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Constipation<br></td><td class="Rrule" align="center" valign="top">290 (11.3)<br></td><td class="Rrule" align="center" valign="top">304 (11.8)<br></td><td class="Rrule" align="center" valign="top">6 (0.2)<br></td><td class="Rrule" align="center" valign="top">2 (&lt;0.1)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Nausea<br></td><td class="Rrule" align="center" valign="top">221&nbsp;(8.6)<br></td><td class="Rrule" align="center" valign="top">212&nbsp;(8.2)<br></td><td class="Rrule" align="center" valign="top">3 (0.1)<br></td><td class="Rrule" align="center" valign="top">10 (0.4)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Diarrhea NOS<br></td><td class="Rrule" align="center" valign="top">128&nbsp;(5)<br></td><td class="Rrule" align="center" valign="top">143&nbsp;(5.6)<br></td><td class="Rrule" align="center" valign="top">12 (0.5)<br></td><td class="Rrule" align="center" valign="top">8 (0.3)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Metabolic Disorders</span><br></td><td class="Rrule" align="center" valign="top">551 (21.5)<br></td><td class="Rrule" align="center" valign="top">537 (20.9)<br></td><td class="Rrule" align="center" valign="top">24 (0.9)<br></td><td class="Rrule" align="center" valign="top">32 (1.2)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Hypercholesterolemia<br></td><td class="Rrule" align="center" valign="top">401 (15.6)<br></td><td class="Rrule" align="center" valign="top">398 (15.5)<br></td><td class="Rrule" align="center" valign="top">2 (&lt;0.1)<br></td><td class="Rrule" align="center" valign="top">5 (0.2)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Reproductive Disorders</span><br></td><td class="Rrule" align="center" valign="top">303 (11.8)<br></td><td class="Rrule" align="center" valign="top">357 (13.9)<br></td><td class="Rrule" align="center" valign="top">9 (0.4)<br></td><td class="Rrule" align="center" valign="top">8 (0.3)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Vaginal Hemorrhage<br></td><td class="Rrule" align="center" valign="top">123&nbsp;(4.8)<br></td><td class="Rrule" align="center" valign="top">171&nbsp;(6.6)<br></td><td class="Rrule" align="center" valign="top">2 (&lt;0.1)<br></td><td class="Rrule" align="center" valign="top">5 (0.2)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Vulvovaginal Dryness<br></td><td class="Rrule" align="center" valign="top">137&nbsp;(5.3)<br></td><td class="Rrule" align="center" valign="top">127&nbsp;(4.9)<br></td><td class="Rrule" align="center" valign="top">0 -<br></td><td class="Rrule" align="center" valign="top">0 -<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Psychiatric Disorders</span><br></td><td class="Rrule" align="center" valign="top">320 (12.5)<br></td><td class="Rrule" align="center" valign="top">276 (10.7)<br></td><td class="Rrule" align="center" valign="top">21 (0.8)<br></td><td class="Rrule" align="center" valign="top">16 (0.6)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Insomnia<br></td><td class="Rruleonsi" align="center" valign="top">149&nbsp;(5.8)<br></td><td class="Rrule" align="center" valign="top">120&nbsp;(4.7)<br></td><td class="Rrule" align="center" valign="top">2 (&lt;0.1)<br></td><td class="Rrule" align="center" valign="top">2 (&lt;0.1)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Respiratory Disorders</span><br></td><td class="Rrule" align="center" valign="top">279 (10.9)<br></td><td class="Rrule" align="center" valign="top">260 (10.1)<br></td><td class="Rrule" align="center" valign="top">30 (1.2)<br></td><td class="Rrule" align="center" valign="top">28 (1.1)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">&nbsp;</span><br></td><td class="Rrule" valign="top">Dyspnea<br></td><td class="Rrule" align="center" valign="top">140&nbsp;(5.5)<br></td><td class="Rrule" align="center" valign="top">137&nbsp;(5.3)<br></td><td class="Rrule" align="center" valign="top">21 (0.8)<br></td><td class="Rrule" align="center" valign="top">18 (0.7)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Investigations</span><br></td><td class="Rrule" align="center" valign="top">184&nbsp;(7.2)<br></td><td class="Rrule" align="center" valign="top">147&nbsp;(5.7)<br></td><td class="Rrule" align="center" valign="top">13 (0.5)<br></td><td class="Rrule" align="center" valign="top">13 (0.5)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Infections and Infestations</span><br></td><td class="Rrule" align="center" valign="top">166&nbsp;(6.5)<br></td><td class="Rrule" align="center" valign="top">163&nbsp;(6.3)<br></td><td class="Rrule" align="center" valign="top">40 (1.6)<br></td><td class="Rrule" align="center" valign="top">33 (1.3)<br></td></tr><tr class="Last"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Renal Disorders</span><br></td><td class="Rrule" align="center" valign="top">130&nbsp;(5.1)<br></td><td class="Rrule" align="center" valign="top">100&nbsp;(3.9)<br></td><td class="Rrule" align="center" valign="top">12 (0.5)<br></td><td class="Rrule" align="center" valign="top">6 (0.2)<br></td></tr></tbody></table><br>Based on a median follow-up of patients for 28&nbsp;months, the incidence of clinical fractures from the core randomized study in patients who received letrozole tablets was 5.9% (152) and placebo was 5.5% (142).&nbsp;The incidence of self-reported osteoporosis was higher in patients who received letrozole tablets 6.9% (176) than in patients who received placebo 5.5% (141).&nbsp;Bisphosphonates were administered to 21.1% of the patients who received letrozole tablets and 18.7% of the patients who received placebo.<br>&nbsp;<br>The incidence of cardiovascular ischemic events&nbsp;from the core randomized study was comparable between patients who received letrozole tablets 6.8% (175) and placebo 6.5% (167).<br><br>A patient-reported measure that captures treatment impact on important symptoms associated with estrogen deficiency demonstrated a difference in favor of placebo for vasomotor and sexual symptom domains.<br>&nbsp;<br><span class="Italics"><span class="Bold">Bone Sub-study:</span></span>&nbsp;<span class="Italics">[see <a href="#Section_5.1">Warnings and Precautions&nbsp;(5.1)</a>].</span><br>&nbsp;<br><span class="Italics"><span class="Bold">Lipid Sub-study:</span></span><span class="Bold">&nbsp;</span>In the extended adjuvant setting, based on a median duration of follow-up of 62 months,&nbsp;there was no significant difference between letrozole tablets and placebo in total cholesterol or in any lipid fraction at any time over 5 years. Use of lipid lowering drugs or dietary management of elevated lipids was allowed. <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>].</span></div><div class="Section"><a name="nlm42229-5"></a><a name="Section_6.3"></a><a name="section-6.3"></a><p></p><h2>6.3 Updated Analysis, Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 60 Months</h2><br>The extended adjuvant treatment trial was unblinded early&nbsp;[<span class="Italics">see <a href="#Section_6.2">Adverse Reactions  ( 6.2 )</a></span>].&nbsp;At the updated (final analysis), overall the side effects seen were consistent to those seen at a median treatment duration of 24 months.<br>&nbsp;<br>During treatment or within 30 days of stopping treatment (median duration of treatment 60 months) a higher rate of fractures was observed for letrozole tablets (10.4%) compared to placebo (5.8%), as also a higher rate of osteoporosis (letrozole tablets 12.2% vs placebo 6.4%).<br>&nbsp;<br>Based on 62 months median duration of follow-up in the randomized letrozole arm in the Safety population the incidence of new fractures at any time after randomization was 13.3% for letrozole and 7.8% for placebo.&nbsp;The incidence of new osteoporosis was 14.5% for letrozole and 7.8% for placebo.<br>&nbsp;<br>During treatment or within 30 days of stopping treatment (median duration of treatment 60 months) the incidence of cardiovascular events was 9.8% for letrozole tablets and 7.0% for placebo.<br>&nbsp;<br>Based on 62 months median duration of follow-up in the randomized letrozole arm in the Safety population the incidence of cardiovascular disease at any time after randomization was 14.4% for letrozole and 9.8% for placebo.<br>&nbsp;<br>Lipid sub-study: In the extended adjuvant setting, based on a median duration of follow-up of 62 months, there was no significant difference between letrozole tablets and placebo in total cholesterol or in any lipid fraction over 5 years. Use of lipid lowering drugs or dietary management of elevated lipids was allowed. <span class="Italics">[see <a href="#Section_5.2">Warnings and Precautions (5.2)</a>]</span></div><div class="Section"><a name="nlm42229-5"></a><a name="Section_6.4"></a><a name="section-6.4"></a><p></p><h2>6.4 First-Line Treatment of Advanced Breast Cancer</h2><br>A total of 455 patients were treated for a median time of exposure of 11 months. The incidence of adverse reactions was similar for letrozole tablets and tamoxifen. The most frequently reported adverse reactions were bone pain, hot flushes, back pain, nausea, arthralgia and dyspnea. Discontinuations for adverse reactions other than progression of tumor occurred in 10/455 (2%) of patients on letrozole tablets and in 15/455 (3%) of patients on tamoxifen.<br>&nbsp;<br>Adverse reactions, regardless of relationship to study drug, that were reported in at least 5% of the patients treated with letrozole tablets 2.5 mg or tamoxifen 20 mg in the first-line treatment study are shown in Table 3.<br>&nbsp;<br><span class="Bold">Table&nbsp;3:&nbsp;&nbsp;Percentage (%) of Patients with Adverse Reactions</span><br><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="Botrule First"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Adverse</span><span class="Bold">Reaction</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">Letrozole tablets</span><br><span class="Bold">2.5 mg</span><br><span class="Bold">(N=455)</span><br><span class="Bold">%</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">tamoxifen</span><br><span class="Bold">20 mg</span><br><span class="Bold">(N=455)</span><br><span class="Bold">%</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">General Disorders</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Fatigue<br></td><td class="Rrule" align="center" valign="top">13<br></td><td class="Rrule" align="center" valign="top">13<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Chest Pain<br></td><td class="Rrule" align="center" valign="top">8<br></td><td class="Rrule" align="center" valign="top">9<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Edema Peripheral<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">6<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Pain NOS<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">7<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Weakness<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">4<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Investigations</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Weight Decreased<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">5<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Vascular Disorders</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Hot Flushes<br></td><td class="Rrule" align="center" valign="top">19<br></td><td class="Rrule" align="center" valign="top">16<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Hypertension<br></td><td class="Rrule" align="center" valign="top">8<br></td><td class="Rrule" align="center" valign="top">4<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Gastrointestinal Disorders</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Nausea<br></td><td class="Rrule" align="center" valign="top">17<br></td><td class="Rrule" align="center" valign="top">17<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Constipation<br></td><td class="Rrule" align="center" valign="top">10<br></td><td class="Rrule" align="center" valign="top">11<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Diarrhea<br></td><td class="Rrule" align="center" valign="top">8<br></td><td class="Rrule" align="center" valign="top">4<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Vomiting<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">8<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Infections/Infestations</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Influenza<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">4<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Urinary Tract Infection NOS<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">3<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Injury, Poisoning and Procedural Complications</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Post-Mastectomy Lymphedema<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">7<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Metabolism and Nutrition Disorders</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Anorexia<br></td><td class="Rrule" align="center" valign="top">4<br></td><td class="Rrule" align="center" valign="top">6<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Musculoskeletal and Connective Tissue Disorders</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Bone Pain<br></td><td class="Rrule" align="center" valign="top">22<br></td><td class="Rrule" align="center" valign="top">21<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Back Pain<br></td><td class="Rrule" align="center" valign="top">18<br></td><td class="Rrule" align="center" valign="top">19<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Arthralgia<br></td><td class="Rrule" align="center" valign="top">16<br></td><td class="Rrule" align="center" valign="top">15<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Pain in Limb<br></td><td class="Rrule" align="center" valign="top">10<br></td><td class="Rrule" align="center" valign="top">8<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Nervous System Disorders</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Headache NOS<br></td><td class="Rrule" align="center" valign="top">8<br></td><td class="Rrule" align="center" valign="top">7<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Psychiatric Disorders</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Insomnia<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">4<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Reproductive System and Breast Disorders</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Breast Pain<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">7<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Respiratory, Thoracic and Mediastinal Disorders</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Dyspnea<br></td><td class="Rrule" align="center" valign="top">18<br></td><td class="Rrule" align="center" valign="top">17<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Cough<br></td><td class="Rrule" align="center" valign="top">13<br></td><td class="Rrule" align="center" valign="top">13<br></td></tr><tr class="Last"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Chest Wall Pain<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">6<br></td></tr></tbody></table><br>Other less frequent (&le; 2%) adverse reactions considered consequential for both treatment groups, included peripheral thromboembolic events, cardiovascular events, and cerebrovascular events. Peripheral thromboembolic events included venous thrombosis, thrombophlebitis, portal vein thrombosis and pulmonary embolism. Cardiovascular events included angina, myocardial infarction, myocardial ischemia, and coronary heart disease. Cerebrovascular events included transient ischemic attacks, thrombotic or hemorrhagic strokes and development of hemiparesis.</div><div class="Section"><a name="nlm42229-5"></a><a name="Section_6.5"></a><a name="section-6.5"></a><p></p><h2>6.5 Second- Line Treatment of Advanced Breast Cancer</h2><br>Study discontinuations in the megestrol acetate comparison study for adverse reactions other than progression of tumor were 5/188 (2.7%) on letrozole tablets 0.5 mg, in 4/174 (2.3%) on letrozole tablets 2.5 mg, and in 15/190 (7.9%) on megestrol acetate. There were fewer thromboembolic events at both letrozole tablets doses than on the megestrol acetate arm (0.6% vs 4.7%). There was also less vaginal bleeding (0.3% vs 3.2%) on letrozole tablets than on megestrol acetate. In the aminoglutethimide comparison study, discontinuations for reasons other than progression occurred in 6/193 (3.1%) on 0.5 mg letrozole tablets, 7/185 (3.8%) on 2.5 mg letrozole tablets, and 7/178 (3.9%) of patients on aminoglutethimide.<br>&nbsp;<br>Comparisons of the incidence of adverse reactions revealed no significant differences between the high and low dose letrozole tablet groups in either study. Most of the adverse reactions observed in all treatment groups were mild to moderate in severity and it was generally not possible to distinguish adverse reactions due to treatment from the consequences of the patient&rsquo;s metastatic breast cancer, the effects of estrogen deprivation, or intercurrent illness.<br><br>Adverse reactions, regardless of relationship to study drug, that were reported in at least 5% of the patients treated with letrozole tablets 0.5 mg, letrozole tablets 2.5 mg, megestrol acetate, or aminoglutethimide in the two controlled trials are shown in Table 4.<br>&nbsp;<br><span class="Bold">Table 4: Percentage (%) of Patients with Adverse Reactions</span><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="Botrule First"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Adverse</span><span class="Bold">Reaction</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">Pooled</span><br><span class="Bold">letrozole tablets</span><br><span class="Bold">2.5 mg</span><br><span class="Bold">(N=359)</span><br><span class="Bold">%</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">Pooled</span><br><span class="Bold">letrozole tablets</span><br><span class="Bold">0.5 mg</span><br><span class="Bold">(N=380)</span><br><span class="Bold">%</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">&nbsp;</span><br><span class="Bold">megestrol</span><br><span class="Bold">acetate</span><br><span class="Bold">160 mg</span><br><span class="Bold">(N=189)</span><br><span class="Bold">%</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">&nbsp;</span><br><span class="Bold">&nbsp;</span><br><span class="Bold">aminoglutethimide</span><br><span class="Bold">500 mg</span><br><span class="Bold">(N=178)</span><br><span class="Bold">%</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Body as a Whole</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Fatigue<br></td><td class="Rrule" align="center" valign="top">8<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">11<br></td><td class="Rrule" align="center" valign="top">3<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Chest Pain<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">3<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">3<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Peripheral Edema<span class="Sup">1</span><br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">8<br></td><td class="Rrule" align="center" valign="top">3<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Asthenia<br></td><td class="Rrule" align="center" valign="top">4<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">4<br></td><td class="Rrule" align="center" valign="top">5<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Weight Increase<br></td><td class="Rrule" align="center" valign="top">2<br></td><td class="Rrule" align="center" valign="top">2<br></td><td class="Rrule" align="center" valign="top">9<br></td><td class="Rrule" align="center" valign="top">3<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Cardiovascular</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Hypertension<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">6<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Digestive System</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Nausea<br></td><td class="Rrule" align="center" valign="top">13<br></td><td class="Rrule" align="center" valign="top">15<br></td><td class="Rrule" align="center" valign="top">9<br></td><td class="Rrule" align="center" valign="top">14<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Vomiting<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">9<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Constipation<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">9<br></td><td class="Rrule" align="center" valign="top">7<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Diarrhea<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">3<br></td><td class="Rrule" align="center" valign="top">4<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Pain-Abdominal<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">9<br></td><td class="Rrule" align="center" valign="top">8<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Anorexia<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">3<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">5<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Dyspepsia<br></td><td class="Rrule" align="center" valign="top">3<br></td><td class="Rrule" align="center" valign="top">4<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">5<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Infections/Infestations</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Viral Infection<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">3<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Lab Abnormality</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Hypercholesterolemia<br></td><td class="Rrule" align="center" valign="top">3<br></td><td class="Rrule" align="center" valign="top">3<br></td><td class="Rrule" align="center" valign="top">0<br></td><td class="Rrule" align="center" valign="top">6<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Musculoskeletal System</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Musculoskeletal<span class="Sup">2</span><br></td><td class="Rrule" align="center" valign="top">21<br></td><td class="Rrule" align="center" valign="top">22<br></td><td class="Rrule" align="center" valign="top">30<br></td><td class="Rrule" align="center" valign="top">14<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Arthralgia<br></td><td class="Rrule" align="center" valign="top">8<br></td><td class="Rrule" align="center" valign="top">8<br></td><td class="Rrule" align="center" valign="top">8<br></td><td class="Rrule" align="center" valign="top">3<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Nervous System</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Headache<br></td><td class="Rrule" align="center" valign="top">9<br></td><td class="Rrule" align="center" valign="top">12<br></td><td class="Rrule" align="center" valign="top">9<br></td><td class="Rrule" align="center" valign="top">7<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Somnolence<br></td><td class="Rrule" align="center" valign="top">3<br></td><td class="Rrule" align="center" valign="top">2<br></td><td class="Rrule" align="center" valign="top">2<br></td><td class="Rrule" align="center" valign="top">9<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Dizziness<br></td><td class="Rrule" align="center" valign="top">3<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">3<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Respiratory System</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Dyspnea<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">9<br></td><td class="Rrule" align="center" valign="top">16<br></td><td class="Rrule" align="center" valign="top">5<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Coughing<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">5<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Skin and Appendages</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Hot Flushes<br></td><td class="Rrule" align="center" valign="top">6<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">4<br></td><td class="Rrule" align="center" valign="top">3<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Rash<span class="Sup">3</span><br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">4<br></td><td class="Rrule" align="center" valign="top">3<br></td><td class="Rrule" align="center" valign="top">12<br></td></tr><tr class="Last"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Pruritus<br></td><td class="Rrule" align="center" valign="top">1<br></td><td class="Rrule" align="center" valign="top">2<br></td><td class="Rrule" align="center" valign="top">5<br></td><td class="Rrule" align="center" valign="top">3<br></td></tr></tbody></table><br><span class="Sup">1 </span>Includes peripheral edema, leg edema, dependent edema, edema<p class="First"><span class="Sup">2 </span>Includes musculoskeletal pain, skeletal pain, back pain, arm pain, leg pain</p><p><span class="Sup">3</span> Includes rash, erythematous rash, maculopapular rash, psoriasiform rash, vesicular rash</p><br><br>Other less frequent (&lt;5%) adverse reactions considered consequential and reported in at least 3 patients treated with letrozole tablets, included hypercalcemia, fracture, depression, anxiety, pleural effusion, alopecia, increased sweating and vertigo.</div><div class="Section"><a name="nlm42229-5"></a><a name="Section_6.6"></a><a name="section-6.6"></a><p></p><h2>6.6 First and Second-Line Treatment of Advanced Breast Cancer</h2><br>In the combined analysis of the first- and second-line metastatic trials and post-marketing experiences other adverse reactions that were reported were cataract, eye irritation, palpitations, cardiac failure, tachycardia, dysesthesia (including hypesthesia/paresthesia), arterial thrombosis, memory impairment, irritability, nervousness, urticaria, increased urinary frequency, leukopenia, stomatitis cancer pain, pyrexia, vaginal discharge, appetite increase, dryness of skin and mucosa (including dry mouth), and disturbances of taste and thirst.</div><div class="Section"><a name="nlm42229-5"></a><a name="Section_6.7"></a><a name="section-6.7"></a><p></p><h2>6.7 Postmarketing Experience</h2><br>Cases of blurred vision, increased hepatic enzymes, angioedema, anaphylactic reactions, toxic epidermal necrolysis, erythema multiforme, and hepatitis have been reported.</div></div><div class="Section"><a name="nlm34073-7"></a><a name="Section_7"></a><a name="section-7"></a><p></p><h1>7 DRUG INTERACTIONS</h1><br><span class="Italics"><span class="Bold">Tamoxifen</span></span><br>&nbsp;<br>Coadministration of letrozole tablets and tamoxifen 20 mg daily resulted in a reduction of letrozole plasma levels of 38% on average. Clinical experience in the second-line breast cancer trials indicates that the therapeutic effect of letrozole tablets therapy is not impaired if letrozole tablets are administered immediately after tamoxifen.<br>&nbsp;<br><span class="Italics"><span class="Bold">Cimetidine</span></span><br>&nbsp;<br>A pharmacokinetic interaction study with cimetidine showed no clinically significant effect on letrozole pharmacokinetics.<br>&nbsp;<br><span class="Italics"><span class="Bold">Warfarin</span></span><br>&nbsp;<br>An interaction study with warfarin showed no clinically significant effect of letrozole on warfarin pharmacokinetics.<br>&nbsp;<br><span class="Italics"><span class="Bold">Other anticancer agents</span></span><br>&nbsp;<br>There is no clinical experience to date on the use of letrozole tablets in combination with other anticancer agents.</div><div class="Section"><a name="nlm43684-0"></a><a name="Section_8"></a><a name="section-8"></a><p></p><h1>8 USE IN SPECIFIC POPULATIONS</h1><div class="Section"><a name="nlm42228-7"></a><a name="Section_8.1"></a><a name="section-8.1"></a><p></p><h2>8.1 Pregnancy</h2><br><span class="Bold">Pregnancy Category X</span><span class="Italics"> [see <a href="#Section_4">Contraindications (4)</a>].</span> Letrozole tablets may cause fetal harm when administered to a pregnant woman and the clinical benefit to premenopausal women with breast cancer has not been demonstrated.&nbsp;Letrozole tablets are contraindicated in women who are or may become pregnant.&nbsp;If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.<br>&nbsp;<br>Letrozole tablets caused adverse pregnancy outcomes, including congenital malformations, in rats and rabbits at doses much smaller than the daily maximum recommended human dose (MRHD) on a mg/m<span class="Sup">2</span> basis.&nbsp;Effects included increased post-implantation pregnancy loss and resorptions, fewer live fetuses, and fetal malformations affecting the renal and skeletal systems.&nbsp;Animal data and letrozole&rsquo;s mechanism of action raise concerns that letrozole could be a human teratogen as well.<br>&nbsp;<br>Reproduction studies in rats showed embryo and fetal toxicity at letrozole doses during organogenesis equal to or greater than 1/100 the daily maximum recommended human dose (MRHD) (mg/m<span class="Sup">2</span> basis).&nbsp;Adverse effects included:&nbsp;intrauterine mortality; increased resorptions and postimplantation loss; decreased numbers of live fetuses; and fetal anomalies including absence and shortening of renal papilla, dilation of ureter, edema and incomplete ossification of frontal skull and metatarsals.&nbsp;Letrozole doses 1/10 the daily MRHD (mg/m<span class="Sup">2</span> basis) caused fetal domed head and cervical/centrum vertebral fusion.&nbsp;In rabbits, letrozole caused embryo and fetal toxicity at doses about 1/100,000 and 1/10,000 the daily MRHD&nbsp;respectively (mg/m<span class="Sup">2</span> basis).&nbsp;Fetal anomalies included incomplete ossification of the skull, sternebrae, and fore- and hind legs. <span class="Italics">[see <a href="#Section_13.2">Nonclinical Toxicology (13.2)</a>].</span><br>&nbsp;<br>Physicians should discuss the need for adequate contraception with women who are recently menopausal.&nbsp;Contraception should be used until postmenopausal status is clinically well established.</div><div class="Section"><a name="nlm34080-2"></a><a name="Section_8.3"></a><a name="section-8.2"></a><p></p><h2>8.3 Nursing Mothers</h2><br>It is not known if letrozole is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from letrozole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</div><div class="Section"><a name="nlm34081-0"></a><a name="Section_8.4"></a><a name="section-8.3"></a><p></p><h2>8.4 Pediatric Use</h2><br>The safety and effectiveness in pediatric patients have not been established.</div><div class="Section"><a name="nlm34082-8"></a><a name="Section_8.5"></a><a name="section-8.4"></a><p></p><h2>8.5 Geriatric Use</h2><br>The median age of patients in all studies of first-line and second-line treatment of metastatic breast cancer was 64-65 years. About 1/3 of the patients were &ge;70 years old. In the first-line study, patients &ge;70 years of age experienced longer time to tumor progression and higher response rates than patients &lt;70.<br>&nbsp;<br>For the extended adjuvant setting, more than 5,100 postmenopausal women were enrolled in the clinical study.&nbsp;In total, 41% of patients were aged 65 years or older at enrollment, while 12% were 75 or older. In the extended adjuvant setting, no overall differences in safety or efficacy were observed between these older patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.<br>&nbsp;<br>In the adjuvant setting, more than 8,000 postmenopausal women were enrolled in the clinical study.&nbsp;In total, 36 % of patients were aged 65 years or older at enrollment, while 12% were 75 or older. More adverse reactions were generally reported in elderly patients irrespective of study treatment allocation. However, in comparison to tamoxifen, no overall differences with regards to the safety and efficacy profiles were observed between elderly patients and younger patients.</div></div><div class="Section"><a name="nlm34088-5"></a><a name="Section_10"></a><a name="section-9"></a><p></p><h1>10 OVERDOSAGE</h1><br>Isolated cases of letrozole tablets overdose have been reported. In these instances, the highest single dose ingested was 62.5 mg or 25 tablets. While no serious adverse reactions were reported in these cases, because of the limited data available, no firm recommendations for treatment can be made. However, emesis could be induced if the patient is alert. In general, supportive care and frequent monitoring of vital signs are also appropriate. In single-dose studies, the highest dose used was 30 mg, which was well tolerated; in multiple-dose trials, the largest dose of 10 mg was well tolerated.<br>&nbsp;<br>Lethality was observed in mice and rats following single oral doses that were equal to or greater than 2,000 mg/kg (about 4,000 to 8,000 times the daily maximum recommended human dose on a mg/m<span class="Sup">2</span> basis); death was associated with reduced motor activity, ataxia and dyspnea. Lethality was observed in cats following single IV doses that were equal to or greater than 10 mg/kg (about 50 times the daily maximum recommended human dose on a mg/m<span class="Sup">2</span> basis); death was preceded by depressed blood pressure and arrhythmias.</div><div class="Section"><a name="nlm34089-3"></a><a name="Section_11"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><br>Letrozole tablets for oral administration contain 2.5 mg of letrozole, a nonsteroidal aromatase inhibitor (inhibitor of estrogen synthesis). It is chemically described as 4,4'-(1H-1,2,4-Triazol-1-ylmethylene)dibenzonitrile, and its structural formula is<br><div class="Figure"><img src="image.cfm?id=45377&type=img&name=letrozole%2D01.jpg" alt="letrozole chemical structure"></div>&nbsp;<br>Letrozole is a white to yellowish crystalline powder, practically odorless, freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water. It has a molecular weight of 285.31, empirical formula C<span class="Sub">17</span>H<span class="Sub">11</span>N<span class="Sub">5</span>, and a melting range of 184&deg;C-185&deg;C.<br>&nbsp;<br>Letrozole tablets are available as 2.5 mg tablets for oral administration.<br>&nbsp;<br><span class="Italics">Inactive&nbsp;Ingredients: </span>Colloidal silicon dioxide, ferric oxide (yellow), hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch, polyethylene glycol, sodium starch glycolate, talc and titanium dioxide.</div><div class="Section"><a name="nlm34090-1"></a><a name="Section_12"></a><a name="section-11"></a><p></p><h1>12 CLINICAL PHARMACOLOGY</h1><div class="Section"><a name="nlm43679-0"></a><a name="Section_12.1"></a><a name="section-11.1"></a><p></p><h2>12.1 Mechanism of Action</h2><br>The growth of some cancers of the breast is stimulated or maintained by estrogens. Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents). These interventions lead to decreased tumor mass or delayed progression of tumor growth in some women.<br><br>In postmenopausal women, estrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens (primarily androstenedione and testosterone) to estrone and estradiol. The suppression of estrogen biosynthesis in peripheral tissues and in the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme.<br>&nbsp;<br>Letrozole is a nonsteroidal competitive inhibitor of the aromatase enzyme system; it inhibits the conversion of androgens to estrogens. In adult nontumor- and tumor-bearing female animals, letrozole is as effective as ovariectomy in reducing uterine weight, elevating serum LH, and causing the regression of estrogen-dependent tumors. In contrast to ovariectomy, treatment with letrozole does not lead to an increase in serum FSH. Letrozole selectively inhibits gonadal steroidogenesis but has no significant effect on adrenal mineralocorticoid or glucocorticoid synthesis.<br><br>Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues. Treatment of women with letrozole significantly lowers serum estrone, estradiol and estrone sulfate and has not been shown to significantly affect adrenal corticosteroid synthesis, aldosterone synthesis, or synthesis of thyroid hormones.</div><div class="Section"><a name="nlm43681-6"></a><a name="Section_12.2"></a><a name="section-11.2"></a><p></p><h2>12.2 Pharmacodynamics</h2><br>In postmenopausal patients with advanced breast cancer, daily doses of 0.1 mg to 5 mg letrozole tablets suppress plasma concentrations of estradiol, estrone, and estrone sulfate by 75%-95% from baseline with maximal suppression achieved within two-three days. Suppression is dose-related, with doses of 0.5 mg and higher giving many values of estrone and estrone sulfate that were below the limit of detection in the assays. Estrogen suppression was maintained throughout treatment in all patients treated at 0.5 mg or higher.<br><br>Letrozole is highly specific in inhibiting aromatase activity.&nbsp;There is no impairment of adrenal steroidogenesis. No clinically-relevant changes were found in the plasma concentrations of cortisol, aldosterone, 11-deoxycortisol, 17-hydroxy-progesterone, ACTH or in plasma renin activity among postmenopausal patients treated with a daily dose of letrozole tablets 0.1 mg to 5 mg. The ACTH stimulation test performed after 6 and 12 weeks of treatment with daily doses of 0.1, 0.25, 0.5, 1, 2.5, and 5 mg did not indicate any attenuation of aldosterone or cortisol production. Glucocorticoid or mineralocorticoid supplementation is, therefore, not necessary.<br><br>No changes were noted in plasma concentrations of androgens (androstenedione and testosterone) among healthy postmenopausal women after 0.1, 0.5, and 2.5 mg single doses of letrozole tablets or in plasma concentrations of androstenedione among postmenopausal patients treated with daily doses of 0.1 mg to 5 mg. This indicates that the blockade of estrogen biosynthesis does not lead to accumulation of androgenic precursors. Plasma levels of LH and FSH were not affected by letrozole in patients, nor was thyroid function as evaluated by TSH levels, T3 uptake, and T4 levels.</div><div class="Section"><a name="nlm43682-4"></a><a name="Section_12.3"></a><a name="section-11.3"></a><p></p><h2>12.3 Pharmacokinetics</h2><p class="First"><span class="Italics"><span class="Bold">Absorption and Distribution:</span></span>&nbsp;Letrozole is rapidly and completely absorbed from the gastrointestinal tract and absorption is not affected by food. It is metabolized slowly to an inactive metabolite whose glucuronide conjugate is excreted renally, representing the major clearance pathway. About 90% of radiolabeled letrozole is recovered in urine. Letrozole&rsquo;s terminal elimination half-life is about 2 days and steady-state plasma concentration after daily 2.5 mg dosing is reached in 2-6 weeks. Plasma concentrations at steady state are 1.5 to 2 times higher than predicted from the concentrations measured after a single dose, indicating a slight non-linearity in the pharmacokinetics of letrozole upon daily administration of 2.5 mg. These steady-state levels are maintained over extended periods, however, and continuous accumulation of letrozole does not occur. Letrozole is weakly protein bound and has a large volume of distribution (approximately 1.9 L/kg).</p><p><span class="Italics"><span class="Bold">Metabolism and Excretion:</span></span>&nbsp;Metabolism to a pharmacologically-inactive carbinol metabolite (4,4'-methanol-bisbenzonitrile) and renal excretion of the glucuronide conjugate of this metabolite is the major pathway of letrozole clearance. Of the radiolabel recovered in urine, at least 75% was the glucuronide of the carbinol metabolite, about 9% was two unidentified metabolites, and 6% was unchanged letrozole. </p><p>In human microsomes with specific CYP isozyme activity, CYP3A4 metabolized letrozole to the carbinol metabolite while CYP2A6 formed both this metabolite and its ketone analog. In human liver microsomes, letrozole strongly inhibited CYP2A6 and moderately inhibited CYP2C19.</p><p><span class="Italics"><span class="Bold">Pediatric, Geriatric and Race:</span></span>&nbsp;In the study populations (adults ranging in age from 35 to &gt;80 years), no change in pharmacokinetic parameters was observed with increasing age. Differences in letrozole pharmacokinetics between adult and pediatric populations have not been studied. Differences in letrozole pharmacokinetics due to race have not been studied.</p><p><span class="Italics"><span class="Bold">Renal Impairment:</span></span>&nbsp;In a study of volunteers with varying renal function (24-hour creatinine clearance: 9-116&nbsp;mL/min), no effect of renal function on the pharmacokinetics of single doses of 2.5&nbsp;mg of letrozole tablets was found. In addition, in a study of 347 patients with advanced breast cancer, about half of whom received 2.5 mg letrozole tablets and half 0.5 mg letrozole tablets, renal impairment (calculated creatinine clearance: 20-50 mL/min) did not affect steady-state plasma letrozole concentrations.</p><br><span class="Italics"><span class="Bold">Hepatic&nbsp;Impairment:</span></span>&nbsp;In a study of subjects with mild to moderate non-metastatic hepatic dysfunction (e.g.,&nbsp;cirrhosis, Child-Pugh classification A and B), the mean AUC values of the volunteers with moderate hepatic impairment were 37% higher than in normal subjects, but still within the range seen in subjects without impaired function.<br>&nbsp;<br>In a pharmacokinetic study, subjects with liver cirrhosis and severe hepatic impairment (Child-Pugh classification C, which included bilirubins about 2-11 times ULN with minimal to severe ascites) had two-fold increase in exposure (AUC) and 47% reduction in systemic clearance. Breast cancer patients with severe hepatic impairment are thus expected to be exposed to higher levels of letrozole than patients with normal liver function receiving similar doses of this drug. <span class="Italics">[see <a href="#Section_2.5">Dosage and Administration (2.5)</a>]</span></div></div><div class="Section"><a name="nlm43680-8"></a><a name="Section_13"></a><a name="section-12"></a><p></p><h1>13 NONCLINICAL TOXICOLOGY</h1><div class="Section"><a name="nlm34083-6"></a><a name="Section_13.1"></a><a name="section-12.1"></a><p></p><h2>13.1 Carcinogenesis, Mutagenesis , Impairment Of Fertility</h2><br>A conventional carcinogenesis study in mice at doses of 0.6 to 60 mg/kg/day (about 1 to 100 times the daily maximum recommended human dose on a mg/m<span class="Sup">2</span> basis) administered by oral gavage for up to 2 years revealed a dose-related increase in the incidence of benign ovarian stromal tumors. The incidence of combined hepatocellular adenoma and carcinoma showed a significant trend in females when the high dose group was excluded due to low survival. In a separate study, plasma AUC<span class="Sub">0-12hr</span> levels in mice at 60 mg/kg/day were 55 times higher than the AUC<span class="Sub">0-24hr </span>level in breast cancer patients at the recommended dose. The carcinogenicity study in rats at oral doses of 0.1 to 10 mg/kg/day (about 0.4 to 40 times the daily maximum recommended human dose on a mg/m<span class="Sup">2</span> basis) for up to 2 years also produced an increase in the incidence of benign ovarian stromal tumors at 10 mg/kg/day. Ovarian hyperplasia was observed in females at doses equal to or greater than 0.1 mg/kg/day. At 10&nbsp;mg/kg/day, plasma AUC<span class="Sub">0-24hr</span> levels in rats were 80 times higher than the level in breast cancer patients at the recommended dose.<br>&nbsp;<br>Letrozole tablets were not mutagenic in <span class="Italics">in vitro</span> tests (Ames and E.coli bacterial tests) but were observed to be a potential clastogen in <span class="Italics">in vitro</span> assays (CHO K1 and CCL 61 Chinese hamster ovary cells). Letrozole was not clastogenic <span class="Italics">in vivo</span> (micronucleus test in rats).<br>&nbsp;<br>Studies to investigate the effect of letrozole on fertility have not been conducted; however, repeated dosing caused sexual inactivity in females and atrophy of the reproductive tract in males and females at doses of 0.6, 0.1 and 0.03 mg/kg in mice, rats and dogs, respectively (about one, 0.4 and 0.4 the daily maximum recommended human dose on a mg/m<span class="Sup">2</span> basis, respectively).<p class="First">Letrozole administered to young (postnatal day 7) rats for 12 weeks duration at 0.003, 0.03, 0.3 mg/kg/day by oral gavage, resulted in adverse skeletal/growth effects (bone maturation, bone mineral density) and neuroendocrine and reproductive developmental perturbations of the hypothalamic-pituitary axis at exposures less than exposure anticipated at the clinical dose of 2.5 mg/day.&nbsp; Decreased fertility was accompanied by hypertrophy of the hypophysis and testicular changes that included degeneration of the seminiferous tubular epithelium and atrophy of the female reproductive tract.&nbsp; Young rats in this study were allowed to recover following discontinuation of letrozole treatment for 42 days.&nbsp; Histopathological changes were not reversible at clinically relevant exposures.</p></div><div class="Section"><a name="nlm34091-9"></a><a name="Section_13.2"></a><a name="section-12.2"></a><p></p><h2>13.2 Animal Pharmacology and/or Toxicology</h2><br><span class="Italics"><span class="Bold">Reproductive Toxicology:</span></span>Reproduction studies in rats at letrozole doses equal to or greater than 0.003 mg/kg (about 1/100 the daily maximum recommended human dose on a mg/m<span class="Sup">2</span> basis) administered during the period of organogenesis, have shown that letrozole is embryotoxic and fetotoxic, as indicated by intrauterine mortality, increased resorption, increased postimplantation loss, decreased numbers of live fetuses and fetal anomalies including absence and shortening of renal papilla, dilation of ureter, edema and incomplete ossification of frontal skull and metatarsals.&nbsp;Letrozole was teratogenic in rats. A 0.03 mg/kg dose (about 1/10 the daily maximum recommended human dose on a mg/m<span class="Sup">2</span> basis) caused fetal domed head and cervical/centrum vertebral fusion.<br>&nbsp;<br>Letrozole is embryotoxic at doses equal to or greater than 0.002 mg/kg and fetotoxic when administered to rabbits at 0.02 mg/kg (about 1/100,000 and 1/10,000 the daily maximum recommended human dose on a mg/m<span class="Sup">2</span> basis, respectively). Fetal anomalies included incomplete ossification of the skull, sternebrae, and fore- and hind legs.</div></div><div class="Section"><a name="nlm34092-7"></a><a name="Section_14"></a><a name="section-13"></a><p></p><h1>14 CLINICAL STUDIES</h1><div class="Section"><a name="nlm42229-5"></a><a name="Section_14.1"></a><a name="section-13.1"></a><p></p><h2>14.1 Updated Adjuvant Treatment of Early  Breast Cancer</h2><br>In a multicenter study enrolling over 8,000 postmenopausal women with resected, receptor-positive early breast cancer, one of the following treatments was randomized in a double-blind manner:<br>&nbsp;<br>Option 1:<br>&nbsp;<br>A.&nbsp;&nbsp;&nbsp;&nbsp; tamoxifen for 5 years<br>B.&nbsp;&nbsp;&nbsp;&nbsp; Letrozole tablets for 5 years<br>C.&nbsp;&nbsp;&nbsp;&nbsp; tamoxifen for 2 years followed by letrozole tablets for 3 years<br>D.&nbsp;&nbsp;&nbsp;&nbsp; Letrozole tablets for 2 years followed by tamoxifen for 3 years <br>&nbsp;<br>Option 2:<br><br>A.&nbsp;&nbsp;&nbsp;&nbsp; tamoxifen for 5 years<br>B.&nbsp;&nbsp;&nbsp;&nbsp; Letrozole tablets for 5 years <p class="First">The study in the adjuvant setting, BIG 1-98 was designed to answer two primary questions: whether letrozole tablets for 5 years were superior to tamoxifen for 5 years (Primary Core Analysis) and whether switching endocrine treatments at 2 years&nbsp;was superior to continuing the same agent for a total of 5 years (Sequential Treatments Analysis). Selected baseline characteristics for the study population are shown in Table 5.</p><p>The primary endpoint of this trial was disease-free survival (DFS) (i.e., interval between randomization and earliest occurrence of a local, regional, or distant recurrence, or invasive contralateral breast cancer, or death from any cause). The secondary endpoints were overall survival (OS), systemic disease-free survival&nbsp;(SDFS), invasive contralateral breast cancer, time to breast cancer recurrence (TBR) and time to distant metastasis (TDM).</p><p>The Primary Core Analysis (PCA) included all patients and all follow-up in the monotherapy arms in both randomization options, but follow-up in the two sequential treatments arms was truncated 30 days after switching treatments. The PCA was conducted at a median treatment duration of 24 months and a median follow-up of 26 months. Letrozole tablets were superior to tamoxifen in all endpoints except overall survival and contralateral breast cancer [e.g., DFS: hazard ratio, HR 0.79; 95% CI (0.68, 0.92);&nbsp;<span class="Italics">P</span>=0.002; SDFS: HR 0.83; 95% CI (0.70, 0.97);&nbsp;TDM: HR 0.73; 95% CI (0.60, 0.88); OS: HR 0.86; 95% CI (0.70, 1.06).&nbsp;</p><p>In 2005, based on recommendations by the independent Data Monitoring Committee, the tamoxifen arms were unblinded and patients were allowed to complete initial adjuvant therapy with letrozole tablets (if they had received tamoxifen for at least 2 years) or to start extended adjuvant treatment with letrozole tablets (if they had received tamoxifen for at least 4.5 years) if they remained alive and disease-free. In total, 632 patients crossed to letrozole tablets or another aromatase inhibitor. Approximately 70% (448) of these 632 patients crossed to letrozole tablets to complete initial adjuvant therapy and most of these crossed in years 3 to 4. All of these patients were in Option 1.&nbsp;A total of 184 patients started extended adjuvant therapy with letrozole tablets (172 patients) or with another aromatase inhibitor (12 patients). To explore the impact of this selective crossover, results from analyses censoring follow-up at the date of the selective crossover (in the tamoxifen arm) are presented for the Monotherapy Arms Analysis (MAA).</p><p>The PCA allowed the results of letrozole tablets for 5 years compared with tamoxifen for 5 years to be reported in 2005 after a median follow-up of&nbsp;only 26 months.&nbsp;The design of the PCA is not optimal to evaluate the effect of letrozole tablets after a longer time (because follow-up was truncated in two arms at around 25 months). The Monotherapy Arms Analysis (ignoring the two sequential treatment arms) provided follow-up equally as long in each treatment and did not over-emphasize early recurrences as the PCA did. The MAA thus provides the clinically appropriate updated efficacy results in answer to the first primary question, despite the confounding of the tamoxifen reference arm by the selective crossover to letrozole tablets. The updated results for the MAA are summarized in Table 6. Median follow-up for this analysis is 73 months.</p><p>The Sequential Treatments Analysis (STA) addresses the second primary question of the study.&nbsp;The primary analysis for the Sequential Treatments Analysis (STA) was from switch (or equivalent time-point in monotherapy arms) + 30 days (STA-S) with a two-sided test applied to each pair-wise comparison at the 2.5% level. Additional analyses were conducted from randomization (STA-R) but these comparisons (added in light of changing medical practice) were under-powered for efficacy.</p><br><span class="Bold">Table 5: Adjuvant Study - Patient and Disease Characteristics (ITT Population)</span><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="Botrule First"><td class="Lrule Rrule" colspan="2" valign="top">&nbsp; <br></td><td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">Primary Core Analysis </span><br><span class="Bold">(PCA)</span><br></td><td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">Monotherapy Arms Analysis (MAA)</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">&nbsp;</span><br><span class="Bold">&nbsp;</span><br><span class="Bold">Characteristic</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">Letrozole tablets</span><br><span class="Bold">N=4003</span><br><span class="Bold">n (%)</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">tamoxifen</span><br><span class="Bold">N=4007</span><br><span class="Bold">n (%)</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">Letrozole tablets</span><br><span class="Bold">N=2463</span><br><span class="Bold">n (%)</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">tamoxifen</span><br><span class="Bold">N=2459</span><br><span class="Bold">n (%)</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Age (median, years)<br></td><td class="Rrule" align="center" valign="top">61<br></td><td class="Rrule" align="center" valign="top">61<br></td><td class="Rrule" align="center" valign="top">61<br></td><td class="Rrule" align="center" valign="top">61<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Age range (years)<br></td><td class="Rrule" align="center" valign="top">38-89<br></td><td class="Rrule" align="center" valign="top">39-90<br></td><td class="Rrule" align="center" valign="top">38-88<br></td><td class="Rrule" align="center" valign="top">39-90<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Hormone receptor status (%)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">ER+ and/or PgR+<br></td><td class="Rrule" align="center" valign="top">99.7<br></td><td class="Rrule" align="center" valign="top">99.7<br></td><td class="Rrule" align="center" valign="top">99.7<br></td><td class="Rrule" align="center" valign="top">99.7<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Both unknown<br></td><td class="Rrule" align="center" valign="top">0.3<br></td><td class="Rrule" align="center" valign="top">0.3<br></td><td class="Rrule" align="center" valign="top">0.3<br></td><td class="Rrule" align="center" valign="top">0.3<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">Nodal status (%)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Node negative<br></td><td class="Rrule" align="center" valign="top">52<br></td><td class="Rrule" align="center" valign="top">52<br></td><td class="Rrule" align="center" valign="top">50<br></td><td class="Rrule" align="center" valign="top">52<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Node positive<br></td><td class="Rrule" align="center" valign="top">41<br></td><td class="Rrule" align="center" valign="top">41<br></td><td class="Rrule" align="center" valign="top">43<br></td><td class="Rrule" align="center" valign="top">41<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Nodal status unknown<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">7<br></td></tr><tr class="Last"><td class="Lrule Rrule" colspan="2" valign="top">Prior adjuvant chemotherapy (%)<br></td><td class="Rrule" align="center" valign="top">24<br></td><td class="Rrule" align="center" valign="top">24<br></td><td class="Rrule" align="center" valign="top">24<br></td><td class="Rrule" align="center" valign="top">24<br></td></tr></tbody></table><p>&nbsp;<span class="Bold">Table 6: Updated Adjuvant Study Results - Monotherapy Arms Analysis </span></p><p><span class="Bold">(Median Follow-up 73 Months)</span></p><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="Botrule First"><td class="Lrule Rrule" colspan="3" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">Letrozole tablets<br>N=2463</span><br></td><td class="Rrule" align="center" colspan="2" valign="top"><span class="Bold">tamoxifen</span><br><span class="Bold">N=2459</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">Hazard ratio</span><br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="3" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top"><span class="Bold">Events</span><br><span class="Bold">(%)</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">5-year rate</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">Events</span><br><span class="Bold">(%)</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">5-year rate</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">(95% CI)</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold"><span class="Italics">P</span></span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="3" valign="top">Disease-free survival<span class="Sup">1</span><br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">445 (18.1)<br></td><td class="Rrule" align="center" valign="top">87.4<br></td><td class="Rrule" align="center" valign="top">500 (20.3)<br></td><td class="Rrule" align="center" valign="top">84.7<br></td><td class="Rrule" align="center" valign="top">0.87 (0.76, 0.99)<br></td><td class="Rrule" align="center" valign="top">0.03<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="3" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Censor<br></td><td class="Rrule" align="center" valign="top">445<br></td><td class="Rrule" align="center" valign="top">87.4<br></td><td class="Rrule" align="center" valign="top">483<br></td><td class="Rrule" align="center" valign="top">84.2<br></td><td class="Rrule" align="center" valign="top">0.84 (0.73, 0.95)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">0 positive nodes<br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">165<br></td><td class="Rrule" align="center" valign="top">92.2<br></td><td class="Rrule" align="center" valign="top">189<br></td><td class="Rrule" align="center" valign="top">90.3<br></td><td class="Rrule" align="center" valign="top">0.88 (0.72, 1.09)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">1-3 positive nodes<br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">151<br></td><td class="Rrule" align="center" valign="top">85.6<br></td><td class="Rrule" align="center" valign="top">163<br></td><td class="Rrule" align="center" valign="top">83.0<br></td><td class="Rrule" align="center" valign="top">0.85 (0.68, 1.06)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&gt;=4 positive nodes<br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">123<br></td><td class="Rrule" align="center" valign="top">71.2<br></td><td class="Rrule" align="center" valign="top">142<br></td><td class="Rrule" align="center" valign="top">62.6<br></td><td class="Rrule" align="center" valign="top">0.81 (0.64, 1.03)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Adjuvant chemotherapy<br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">119<br></td><td class="Rrule" align="center" valign="top">86.4<br></td><td class="Rrule" align="center" valign="top">150<br></td><td class="Rrule" align="center" valign="top">80.6<br></td><td class="Rrule" align="center" valign="top">0.77 (0.60, 0.98)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" colspan="2" valign="top">No chemotherapy<br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">326<br></td><td class="Rrule" align="center" valign="top">87.8<br></td><td class="Rrule" align="center" valign="top">350<br></td><td class="Rrule" align="center" valign="top">86.1<br></td><td class="Rrule" align="center" valign="top">0.91 (0.78, 1.06)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="3" valign="top">Systemic DFS<span class="Sup">2</span><br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">401<br></td><td class="Rrule" align="center" valign="top">88.5<br></td><td class="Rrule" align="center" valign="top">446<br></td><td class="Rrule" align="center" valign="top">86.6<br></td><td class="Rrule" align="center" valign="top">0.88 (0.77, 1.01)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="3" valign="top">Time to distant metastasis<span class="Sup">3</span><br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">257<br></td><td class="Rrule" align="center" valign="top">92.4<br></td><td class="Rrule" align="center" valign="top">298<br></td><td class="Rrule" align="center" valign="top">90.1<br></td><td class="Rrule" align="center" valign="top">0.85 (0.72, 1.00)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Adjuvant chemotherapy<br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">84<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">109<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" valign="top">&nbsp;0.75 (0.56, 1.00)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">No chemotherapy<br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">173<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">189<br></td><td class="Rrule" align="center" valign="top">-<br></td><td class="Rrule" align="center" valign="top">0.90 (0.73, 1.11)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="3" valign="top">Distant DFS<span class="Sup">4</span><br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">385<br></td><td class="Rrule" align="center" valign="top">89.0<br></td><td class="Rrule" align="center" valign="top">432<br></td><td class="Rrule" align="center" valign="top">87.1<br></td><td class="Rrule" align="center" valign="top">0.87 (0.76, 1.00)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="3" valign="top">Contralateral breast cancer<br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">34<br></td><td class="Rrule" align="center" valign="top">99.2<br></td><td class="Rrule" align="center" valign="top">44<br></td><td class="Rrule" align="center" valign="top">98.6<br></td><td class="Rrule" align="center" valign="top">0.76 (0.49, 1.19)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="3" valign="top">Overall survival<br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">303<br></td><td class="Rrule" align="center" valign="top">91.8<br></td><td class="Rrule" align="center" valign="top">343<br></td><td class="Rrule" align="center" valign="top">90.9<br></td><td class="Rrule" align="center" valign="top">0.87 (0.75, 1.02)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="3" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Censor<br></td><td class="Rrule" align="center" valign="top">303<br></td><td class="Rrule" align="center" valign="top">91.8<br></td><td class="Rrule" align="center" valign="top">338<br></td><td class="Rrule" align="center" valign="top">90.1<br></td><td class="Rrule" align="center" valign="top">0.82 (0.70, 0.96)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">0 positive nodes<br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">107<br></td><td class="Rrule" align="center" valign="top">95.2<br></td><td class="Rrule" align="center" valign="top">121<br></td><td class="Rrule" align="center" valign="top">94.8<br></td><td class="Rrule" align="center" valign="top">0.90 (0.69, 1.16)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">1-3 positive nodes<br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">99<br></td><td class="Rrule" align="center" valign="top">90.8<br></td><td class="Rrule" align="center" valign="top">114<br></td><td class="Rrule" align="center" valign="top">90.6<br></td><td class="Rrule" align="center" valign="top">0.81 (0.62, 1.06)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&gt;=4 positive nodes<br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">92<br></td><td class="Rrule" align="center" valign="top">80.2<br></td><td class="Rrule" align="center" valign="top">104<br></td><td class="Rrule" align="center" valign="top">73.6<br></td><td class="Rrule" align="center" valign="top">0.86 (0.65, 1.14)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Adjuvant chemotherapy<br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">76<br></td><td class="Rrule" align="center" valign="top">91.5<br></td><td class="Rrule" align="center" valign="top">96<br></td><td class="Rrule" align="center" valign="top">88.4<br></td><td class="Rrule" align="center" valign="top">0.79 (0.58, 1.06)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">No chemotherapy<br></td><td class="Rrule" valign="top">ITT<br></td><td class="Rrule" align="center" valign="top">227<br></td><td class="Rrule" align="center" valign="top">91.9<br></td><td class="Rrule" align="center" valign="top">247<br></td><td class="Rrule" align="center" valign="top">91.8<br></td><td class="Rrule" align="center" valign="top">0.91 (0.76, 1.08)<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="10" valign="top">Definition of:<br><span class="Sup">1&nbsp;</span>Disease-free survival: Interval from randomization to earliest event of invasive loco-regional recurrence, distant metastasis, invasive contralateral breast cancer, or death without a prior event<br><span class="Sup">2&nbsp;</span>Systemic disease-free survival: Interval from randomization to invasive regional recurrence, distant metastasis, or death without a prior cancer event<br><span class="Sup">3</span>&nbsp;Time to distant metastasis: Interval from randomization to distant metastasis<br><span class="Sup">4</span>&nbsp;Distant disease-free survival: Interval from randomization to earlier event of relapse in a distant site or death from any cause <br>ITT analysis ignores selective crossover in tamoxifen arms<br>Censored analysis censors follow-up at the date of selective crossover in 632 patients who crossed to letrozole tablets or another aromatase inhibitor after the tamoxifen arms were unblinded in 2005<br></td></tr><tr class="Last"><td class="Lrule Rrule" valign="top"></td><td class="Rrule" valign="top"></td><td class="Rrule" valign="top"></td><td class="Rrule" valign="top"></td><td class="Rrule" valign="top"></td><td class="Rrule" valign="top"></td><td class="Rrule" valign="top"></td><td class="Rrule" valign="top"></td><td class="Rrule" valign="top"></td><td class="Rrule" valign="top"></td></tr></tbody></table><p>Figure 1 shows the Kaplan-Meier curves for Disease-Free Survival Monotherapy Analysis</p><p><span class="Bold">Figure 1 Disease-Free Survival (Median follow-up 73 months, ITT Approach)</span></p><br><br><div class="Figure"><img src="image.cfm?id=45377&type=img&name=letrozole%2D02.jpg" alt="letrozole graph"></div><br>DFS events defined as loco-regional recurrence, distant metastasis, invasive contralateral breast cancer, or death from any cause (i.e., definition excludes second non-breast primary cancers).<br><p>The medians of overall survival for both arms were not reached for the Monotherapy Arms Analysis (MAA). There was no statistically significant difference in overall survival. The hazard ratio for survival in&nbsp;the letrozole tablets arm compared to the&nbsp;tamoxifen arm was 0.87, with&nbsp;95% CI (0.75, 1.02) (see Table 6).</p><p>There were no significant differences in DFS, OS, SDFS, and Distant DFS from switch in the Sequential Treatments Analysis with respect to either monotherapy (e.g., [Tamoxifen 2 years followed by] letrozole tablets 3 years versus tamoxifen beyond 2 years, DFS HR 0.89; 97.5% CI 0.68, 1.15 and [letrozole tablets 2 years followed by] tamoxifen 3 years versus letrozole tablets beyond 2 years, DFS HR 0.93; 97.5% CI 0.71, 1.22).</p><p>There were no significant differences in&nbsp;DFS, OS, SDFS, and Distant DFS from randomization in the Sequential Treatments Analyses.</p></div><div class="Section"><a name="nlm42229-5"></a><a name="Section_14.2"></a><a name="section-13.2"></a><p></p><h2>14.2 Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 24 Months</h2><br>A double-blind, randomized, placebo-controlled trial of letrozole tablets&nbsp;was performed in over 5,100 postmenopausal women with receptor-positive or unknown primary breast cancer who were disease free after 5 years of adjuvant treatment with tamoxifen.<br>&nbsp;<br>The planned duration of treatment for patients in the study was 5 years, but the trial was terminated early because of an interim analysis showing a favorable letrozole tablets effect on time without recurrence or contralateral breast cancer.&nbsp;At the time of unblinding, women had been followed for a median of 28 months, 30% of patients had completed 3 or more years of follow-up and less than 1% of patients had completed 5 years of follow-up.<br>&nbsp;<br>Selected baseline characteristics for the study population are shown in Table&nbsp;7.<br>&nbsp;<br><span class="Bold">Table 7: Selected Study Population Demographics (Modified ITT Population)</span><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="Botrule First"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Baseline Status</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">Letrozole tablets</span><br><span class="Bold">N=2582</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">Placebo</span><br><span class="Bold">N=2586</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Hormone Receptor Status (%)</span><br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">ER+ and/or PgR+<br></td><td class="Rrule" align="center" valign="top">98<br></td><td class="Rrule" align="center" valign="top">98<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Both Unknown<br></td><td class="Rrule" align="center" valign="top">2<br></td><td class="Rrule" align="center" valign="top">2<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Nodal Status (%)</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Node Negative<br></td><td class="Rrule" align="center" valign="top">50<br></td><td class="Rrule" align="center" valign="top">50<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Node Positive<br></td><td class="Rrule" align="center" valign="top">46<br></td><td class="Rrule" align="center" valign="top">46<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Nodal Status Unknown<br></td><td class="Rrule" align="center" valign="top">4<br></td><td class="Rrule" align="center" valign="top">4<br></td></tr><tr class="Last"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Chemotherapy</span><br></td><td class="Rrule" align="center" valign="top">46<br></td><td class="Rrule" align="center" valign="top">46<br></td></tr></tbody></table><p class="First">Table 8&nbsp;shows the study results.&nbsp;Disease-free survival was measured as the time from randomization to the earliest event of loco-regional or distant recurrence of the primary disease or development of contralateral breast cancer or death. DFS by hormone receptor status, nodal status and adjuvant chemotherapy were similar to the overall results.&nbsp;Data were premature for an analysis of survival.</p><p><span class="Bold">Table 8: Extended Adjuvant Study Results</span></p><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">Letrozole tablets<br>N = 2582</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">Placebo <br>N = 2586</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">Hazard Ratio <br>(95% CI)</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold"><span class="Italics">P</span>-Value</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Disease Free Survival (DFS)<span class="Sup">1</span>&nbsp;Events</span><br></td><td class="Rrule" align="center" valign="top">122 (4.7%)<br></td><td class="Rrule" align="center" valign="top">193 (7.5%)<br></td><td class="Rrule" align="center" valign="top">0.62 (0.49, 0.78)<span class="Sup">2</span><br></td><td class="Rrule" align="center" valign="top">0.00003<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Local Breast &nbsp;&nbsp;Recurrence<br></td><td class="Rrule" align="center" valign="top">9<br></td><td class="Rrule" align="center" valign="top">22<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Local Chest Wall Recurrence<br></td><td class="Rrule" align="center" valign="top">2<br></td><td class="Rrule" align="center" valign="top">8<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Regional Recurrence<br></td><td class="Rrule" align="center" valign="top">7<br></td><td class="Rrule" align="center" valign="top">4<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Distant Recurrence<br></td><td class="Rrule" align="center" valign="top">55<br></td><td class="Rrule" align="center" valign="top">92<br></td><td class="Rrule" align="center" valign="top">0.61 (0.44, 0.84)<br></td><td class="Rrule" align="center" valign="top">0.003<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Contralateral Breast Cancer<br></td><td class="Rrule" align="center" valign="top">19<br></td><td class="Rrule" align="center" valign="top">29<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Deaths Without Recurrence or Contralateral Breast Cancer<br></td><td class="Rrule" align="center" valign="top">30<br></td><td class="Rrule" align="center" valign="top">38<br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Last"><td class="Lrule Rrule" colspan="6" valign="top">CI = confidence interval for hazard ratio. Hazard ratio of less than 1.0 indicates difference in favor of letrozole tablets (lesser&nbsp;risk of recurrence); hazard ratio greater than 1.0 indicates difference in favor of placebo (higher risk of recurrence with letrozole tablets).<br><span class="Sup">1</span>&nbsp;First event of loco-regional recurrence, distant relapse, contralateral breast cancer or death from any cause <br><span class="Sup">2&nbsp;</span>Analysis stratified by receptor status, nodal status and prior adjuvant chemotherapy (stratification factors as at randomization). <span class="Italics">P</span>-value based on stratified logrank test.<span class="Bold"></span><br></td></tr></tbody></table></div><div class="Section"><a name="nlm42229-5"></a><a name="Section_14.3"></a><a name="section-13.3"></a><p></p><h2>14.3 Updated Analyses of Extended Adjuvant Treatment of Early Breast Cancer, Median Treatment Duration of 60 Months</h2><br><p class="First"><span class="Bold">Table 9: &nbsp;Update of Extended Adjuvant Study Results</span></p><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="Botrule First"><td class="Lrule Rrule" colspan="2" valign="top">&nbsp; <br></td><td class="Rrule" valign="top"><span class="Bold">Letrozole tablets</span><span class="Bold"><br>N = 2582</span><br><span class="Bold">(%)</span><br></td><td class="Rrule" valign="top"><span class="Bold">Placebo <br>N = 2586</span><br><span class="Bold">(%)</span><br></td><td class="Rrule" valign="top"><span class="Bold">Hazard Ratio<span class="Sup">1 </span><br>(95% CI)</span><br></td><td class="Rrule" valign="top"><span class="Bold"><span class="Italics">P</span>-Value<span class="Sup">2</span></span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Disease Free Survival (DFS) events<span class="Sup">3</span></span><br></td><td class="Rrule" valign="top">344 (13.3)<br></td><td class="Rrule" valign="top">402 (15.5)<br></td><td class="Rrule" valign="top">0.89 (0.77, 1.03)<br></td><td class="Rrule" valign="top">0.12<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Breast cancer recurrence</span><br>(Protocol definition of DFS events<span class="Sup">4</span>) <br></td><td class="Rrule" valign="top">209<br></td><td class="Rrule" valign="top">286<br></td><td class="Rrule" valign="top">0.75 (0.63, 0.89)<br></td><td class="Rrule" valign="top">0.001<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Local Breast Recurrence<br></td><td class="Rrule" valign="top">15<br></td><td class="Rrule" valign="top">44<br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Local Chest Wall Recurrence<br></td><td class="Rrule" valign="top">6<br></td><td class="Rrule" valign="top">14<br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Regional Recurrence<br></td><td class="Rrule" valign="top">10<br></td><td class="Rrule" valign="top">8<br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Distant Recurrence<br></td><td class="Rrule" valign="top">140<br></td><td class="Rrule" valign="top">167<br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Distant recurrence (first or subsequent events)<br>Contralateral Breast Cancer<br></td><td class="Rrule" valign="top"><br>142<br>37<br></td><td class="Rrule" valign="top"><br>169<br>53<br></td><td class="Rrule" valign="top">0.88 (0.70, 1.10)<br></td><td class="Rrule" valign="top">0.246<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">Deaths Without Recurrence or Contralateral Breast Cancer<br></td><td class="Rrule" valign="top">135<br></td><td class="Rrule" valign="top">116<br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Last"><td class="Lrule Rrule" colspan="6" valign="top"><span class="Sup">1 </span>Adjusted by receptor status, nodal status and prior chemotherapy<br><span class="Sup">2</span> Stratified logrank test, stratified by receptor status, nodal status and prior chemotherapy<br><span class="Sup">3</span> DFS events defined as earliest of loco-regional recurrence, distant metastasis, contralateral breast cancer or death from any cause, and ignoring switches to letrozole tablets in 60% of the placebo arm.<br><span class="Sup">4</span> Protocol definition does not include deaths from any cause&nbsp;<br></td></tr></tbody></table><p>Updated analyses were conducted at a median follow-up of&nbsp;62&nbsp;months. In the letrozole tablets arm,&nbsp;71%&nbsp;of the patients were treated for a least 3 years&nbsp;and 58% of patients completed at least 4.5 years of&nbsp;extended adjuvant treatment. After the unblinding of the study at a median follow-up of 28 months, approximately&nbsp;60% of the selected patients&nbsp;in the placebo arm opted to switch to letrozole tablets.</p><br>In this updated analysis shown&nbsp;in Table 9, letrozole tablets significantly reduced the risk of breast cancer recurrence or contralateral breast cancer compared with placebo (HR 0.75; 95% CI 0.63, 0.89; <span class="Italics">P</span>=0.001). However, in the updated DFS analysis (interval between randomization and earliest event of loco-regional recurrence, distant metastasis, contralateral breast cancer, or death from any cause) the treatment difference was heavily diluted by 60% of the patients in the placebo arm&nbsp;switching to letrozole tablets and accounting for 64% of the total placebo patient- years of follow-up. Ignoring these switches, the risk of DFS event was reduced by a non-significant 11% (HR 0.89; 95% CI&nbsp;0.77, 1.03). There was no significant difference in distant disease-free survival or overall survival.</div><div class="Section"><a name="nlm42229-5"></a><a name="Section_14.4"></a><a name="section-13.4"></a><p></p><h2>14.4 First-Line Treatment of Advanced Breast Cancer</h2><br>A randomized, double-blind, multinational trial compared letrozole tablets&nbsp;2.5 mg with tamoxifen 20 mg in 916 postmenopausal patients with locally advanced (Stage IIIB or loco-regional recurrence not amenable to treatment with surgery or radiation) or metastatic breast cancer. Time to progression (TTP) was the primary endpoint of the trial. Selected baseline characteristics for this study are shown in Table 10.<br>&nbsp;<br><span class="Bold">Table 10: Selected Study Population Demographics</span><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="Botrule First"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Baseline Status</span><br></td><td class="Rrule" valign="top"><span class="Bold">Letrozole tablets </span><br><span class="Bold">N=458</span><span class="Bold"></span><br></td><td class="Rrule" valign="top"><span class="Bold">tamoxifen</span><br><span class="Bold">N=458</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Stage of Disease</span><br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">IIIB<br></td><td class="Rrule" valign="top">6%<br></td><td class="Rrule" valign="top">7%<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">IV<br></td><td class="Rrule" valign="top">93%<br></td><td class="Rrule" valign="top">92%<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Receptor Status</span><span class="Bold"></span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">ER and PgR&nbsp;Positive<br></td><td class="Rrule" valign="top">38%<br></td><td class="Rrule" valign="top">41%<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">ER or PgR Positive<br></td><td class="Rrule" valign="top">26%<br></td><td class="Rrule" valign="top">26%<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">Both Unknown<br></td><td class="Rrule" valign="top">34%<br></td><td class="Rrule" valign="top">33%<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">ER<span class="Sup">-</span> or PgR<span class="Sup">-</span>/Other Unknown<br></td><td class="Rrule" valign="top">&lt;1%<br></td><td class="Rrule" valign="top">0<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Previous Antiestrogen Therapy</span><br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">Adjuvant<br></td><td class="Rrule" valign="top">19%<br></td><td class="Rrule" valign="top">18%<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">None<br></td><td class="Rrule" valign="top">81%<br></td><td class="Rrule" valign="top">82%<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Dominant Site of Disease</span><br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">Soft Tissue<br></td><td class="Rrule" valign="top">25%<br></td><td class="Rrule" valign="top">25%<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">Bone<br></td><td class="Rrule" valign="top">32%<br></td><td class="Rrule" valign="top">29%<br></td></tr><tr class="Last"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">Viscera<br></td><td class="Rrule" valign="top">43%<br></td><td class="Rrule" valign="top">46%<br></td></tr></tbody></table><br>&nbsp;<br>Letrozole tablets were superior to tamoxifen in TTP and rate of objective tumor response (see Table 11).<br>&nbsp;<br>Table 11&nbsp;summarizes the results of the trial, with a total median follow-up of approximately 32 months. (All analyses are unadjusted and use 2-sided <span class="Italics">P</span>-values.)<p class="First"><span class="Bold">Table 11: Results of First-Line Treatment of Advanced Breast Cancer</span></p><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="Botrule First"><td class="Lrule Rrule" align="center" colspan="2" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top"><span class="Bold">Letrozole tablets </span><br><span class="Bold">2.5 mg</span><br><span class="Bold">N=453</span><span class="Bold"></span><br></td><td class="Rrule" valign="top"><span class="Bold">tamoxifen</span><br><span class="Bold">20 mg</span><br><span class="Bold">N=454</span><br></td><td class="Rrule" valign="top"><span class="Bold">Hazard or Odds</span><br><span class="Bold">Ratio (95% CI)</span><br><span class="Bold"><span class="Italics">P</span>-Value (2-Sided)</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Median Time to Progression</span><br></td><td class="Rrule" valign="top">9.4 months<br></td><td class="Rrule" valign="top">6.0 months<br></td><td class="Rrule" valign="top">0.72 (0.62, 0.83)<span class="Sup">1</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top"><span class="Italics">P</span>&lt;0.0001<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Objective Response Rate</span><br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">(CR + PR)<br></td><td class="Rrule" valign="top">145 (32%)<br></td><td class="Rrule" valign="top">95 (21%)<br></td><td class="Rrule" valign="top">1.77 (1.31, 2.39)<span class="Sup">2</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top"><span class="Italics">P</span>=0.0002<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">(CR)<br></td><td class="Rrule" valign="top">42 (9%)<br></td><td class="Rrule" valign="top">15 (3%)<br></td><td class="Rrule" valign="top">2.99 (1.63, 5.47)<span class="Sup">2</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top"><span class="Italics">P</span>=0.0004<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Duration of Objective Response</span><br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">Median<br></td><td class="Rrule" valign="top">18 months <br></td><td class="Rrule" valign="top">16 months <br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">(N=145)<br></td><td class="Rrule" valign="top">(N=95)<br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Overall Survival</span><br></td><td class="Rrule" valign="top">35 months <br></td><td class="Rrule" valign="top">32 months<br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Last"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">(N=458)<br></td><td class="Rrule" valign="top">(N=458)<br></td><td class="Rrule" valign="top"><span class="Italics">P</span>=0.5136<span class="Sup">3</span><br></td></tr></tbody></table><br><span class="Sup">1</span> Hazard ratio<br><span class="Sup">2</span> Odds ratio<br><span class="Sup">3</span> Overall logrank test<br>&nbsp;<br>Figure 2&nbsp;shows the Kaplan-Meier curves for TTP<br>.<br><span class="Bold">Figure 2&nbsp;&nbsp;Kaplan-Meier Estimates of Time to Progression (Tamoxifen Study)</span><br><div class="Figure"><img src="image.cfm?id=45377&type=img&name=letrozole%2D03.jpg" alt="letrozole graph"></div><br>Table 12&nbsp;shows results in the subgroup of women who had received prior antiestrogen adjuvant therapy, Table 13, results by disease site and Table 14, the results by receptor status.<br><br>&nbsp;<br><span class="Bold">Table 12: Efficacy in Patients Who Received Prior&nbsp;Antiestrogen Therapy</span><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="Botrule First"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Variable</span><span class="Bold"></span><br></td><td class="Rrule" valign="top"><span class="Bold">Letrozole tablets &nbsp;</span><br><span class="Bold">2.5 mg</span><br><span class="Bold">N=84</span><span class="Bold"></span><br></td><td class="Rrule" valign="top"><span class="Bold">tamoxifen</span><br><span class="Bold">20 mg</span><br><span class="Bold">N=83</span><span class="Bold"></span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Median Time to Progression</span> (95% CI)<br></td><td class="Rrule" valign="top">8.9 months (6.2, 12.5) <br></td><td class="Rrule" valign="top">5.9 months (3.2, 6.2)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">Hazard Ratio for TTP (95% CI) <br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">0.60 (0.43, 0.84)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Objective Response Rate</span><span class="Bold"></span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">(CR + PR)<br></td><td class="Rrule" valign="top">22 (26%)<br></td><td class="Rrule" valign="top">7 (8%)<br></td></tr><tr class="Last"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">Odds Ratio for&nbsp;Response (95% CI)<br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">3.85 (1.50, 9.60)<br></td></tr></tbody></table><br>&nbsp;<br>Hazard ratio less than 1 or odds ratio greater than 1 favors letrozole tablets; hazard ratio greater than 1 or odds ratio less than 1 favors tamoxifen.<br>&nbsp;<span class="Bold">Table 13: Efficacy by Disease Site</span><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="Botrule First"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top"><span class="Bold">Letrozole tablets &nbsp;</span><br><span class="Bold">2.5 mg</span><br></td><td class="Rrule" valign="top"><span class="Bold">tamoxifen</span><br><span class="Bold">20 mg</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Dominant Disease Site</span><br></td><td class="Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Soft Tissue:</span><br></td><td class="Rrule" valign="top">N=113<br></td><td class="Rrule" valign="top">N=115<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">Median TTP<br></td><td class="Rrule" valign="top">12.1 months<br></td><td class="Rrule" valign="top">6.4 months<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">Objective Response Rate<br></td><td class="Rrule" valign="top">50%<br></td><td class="Rrule" valign="top">34%<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Bone:</span><br></td><td class="Rrule" valign="top">N=145<br></td><td class="Rrule" valign="top">N=131<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">Median TTP<br></td><td class="Rrule" valign="top">9.5 months<br></td><td class="Rrule" valign="top">6.3 months<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">Objective Response Rate<br></td><td class="Rrule" valign="top">23%<br></td><td class="Rrule" valign="top">15%<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">Viscera:</span><br></td><td class="Rrule" valign="top">N=195<br></td><td class="Rrule" valign="top">N=208<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">Median TTP<br></td><td class="Rrule" valign="top">8.3 months<br></td><td class="Rrule" valign="top">4.6 months<br></td></tr><tr class="Last"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">&nbsp; </span><br></td><td class="Rrule" valign="top">Objective Response Rate<br></td><td class="Rrule" valign="top">28%<br></td><td class="Rrule" valign="top">17%<br></td></tr></tbody></table><p><span class="Bold">Table 14: Efficacy by Receptor Status</span></p><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="Botrule First"><td class="Lrule Rrule" valign="top"><span class="Bold">Variable</span><br></td><td class="Rrule" valign="top"><span class="Bold">Letrozole tablets</span><br><span class="Bold">2.5 mg</span><br></td><td class="Rrule" valign="top"><span class="Bold">tamoxifen</span><br><span class="Bold">20 mg</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">Receptor Positive</span><br></td><td class="Rrule" valign="top">N=294<br></td><td class="Rrule" valign="top">N=305<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp; Median Time to&nbsp;Progression (95% CI)<br></td><td class="Rrule" valign="top">9.4 months (8.9, 11.8)<br></td><td class="Rrule" valign="top">6.0 months (5.1, 8.5)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp; Hazard Ratio for TTP (95% CI)<br></td><td class="Rrule" valign="top">0.69 (0.58, 0.83)<br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp; Objective Response Rate (CR+PR)<br></td><td class="Rrule" valign="top">97 (33%)<br></td><td class="Rrule" valign="top">66 (22%)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp; Odds Ratio for Response (95% CI)<br></td><td class="Rrule" valign="top">1.78 (1.20, 2.60)<br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">Receptor Unknown</span><br></td><td class="Rrule" valign="top">N=159<br></td><td class="Rrule" valign="top">N=149<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp; Median Time to&nbsp;Progression (95% CI)<br></td><td class="Rrule" valign="top">9.2 months (6.1, 12.3)<br></td><td class="Rrule" valign="top">6.0 months (4.1, 6.4)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp; Hazard Ratio for TTP (95% CI)<br></td><td class="Rrule" valign="top">&nbsp;0.77 (0.60, 0.99)<br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp; Objective Response Rate (CR+PR)<br></td><td class="Rrule" valign="top">48 (30%)<br></td><td class="Rrule" valign="top">29 (20%)<br></td></tr><tr class="Last"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp; Odds Ratio for Response (95% CI)<br></td><td class="Rrule" valign="top">1.79 (1.10, 3.00)<br></td><td class="Rrule" valign="top">&nbsp; <br></td></tr></tbody></table><br>&nbsp;<br>Hazard ratio less than 1 or odds ratio greater than 1 favors letrozole tablets; hazard ratio greater than 1 or odds ratio less than 1 favors tamoxifen.<br>&nbsp;<br>Figure 3&nbsp;shows the Kaplan-Meier curves for survival.<br>&nbsp;<br><span class="Bold">Figure 3&nbsp;&nbsp;Survival by Randomized Treatment Arm</span><br><div class="Figure"><img src="image.cfm?id=45377&type=img&name=letrozole%2D04.jpg" alt="letrozole graph"></div><br><span class="Bold">Legend:</span>&nbsp;Randomized letrozole tablets:&nbsp;n=458, events 57%, median overall survival 35 months (95% CI 32 to 38 months)<br>&nbsp;<br>Randomized tamoxifen:&nbsp;n=458, events 57%, median overall survival 32 months (95% CI 28 to 37 months)<br>&nbsp;<br>Overall logrank <span class="Italics">P</span>=0.5136 (i.e., there was no significant difference between treatment arms in overall survival).<br><br>The median overall survival was 35 months for the letrozole tablets group and 32 months for the tamoxifen group, with a <span class="Italics">P</span>-value 0.5136.&nbsp;Study design allowed patients to cross over upon progression to the other therapy. Approximately 50% of patients crossed over to the opposite treatment arm and almost all patients who crossed over had done so by 36 months. The median time to crossover was 17 months (letrozole tablets to tamoxifen) and 13 months (tamoxifen to letrozole tablets). In patients who did not cross over to the opposite treatment arm, median survival was 35 months with letrozole tablets (n=219, 95% CI 29 to 43 months) vs 20 months with tamoxifen (n=229, 95% CI 16 to 26 months).</div><div class="Section"><a name="nlm42229-5"></a><a name="Section_14.6"></a><a name="section-13.5"></a><p></p><h2>14.5 Second-Line Treatment of Advanced Breast Cancer</h2><p class="First">Letrozole tablets was initially studied at doses of 0.1 mg to 5.0 mg daily in six non-comparative Phase I/II trials in 181 postmenopausal estrogen/progesterone receptor positive or unknown advanced breast cancer patients previously treated with at least antiestrogen therapy. Patients had received other hormonal therapies and also may have received cytotoxic therapy. Eight (20%) of forty patients treated with letrozole tablets 2.5 mg daily in Phase I/II trials achieved an objective tumor response (complete or partial response).</p><p>Two large randomized, controlled, multinational (predominantly European) trials were conducted in patients with advanced breast cancer who had progressed despite antiestrogen therapy. Patients were randomized to letrozole tablets 0.5 mg daily, letrozole tablets 2.5 mg daily, or a comparator (megestrol acetate 160 mg daily in one study; and aminoglutethimide 250 mg b.i.d. with corticosteroid supplementation in the other study). In each study over 60% of the patients had received therapeutic antiestrogens, and about one-fifth of these patients had had an objective response. The megestrol acetate controlled study was double-blind; the other study was open label. Selected baseline characteristics for each study are shown in Table 15.</p><p>&nbsp;<span class="Bold">Table 15: Selected Study Population Demographics</span></p><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="Botrule First"><td class="Lrule Rrule" valign="top"><span class="Bold">Parameter</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">megestrol acetate</span><br><span class="Bold">study</span><br></td><td class="Rrule" align="center" valign="top"><span class="Bold">aminoglutethimide</span><br><span class="Bold">study</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">No. of Participants</span><br></td><td class="Rrule" align="center" valign="top">552<br></td><td class="Rrule" align="center" valign="top">557<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">Receptor Status</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ER/PR Positive<br></td><td class="Rrule" align="center" valign="top">57%<br></td><td class="Rrule" align="center" valign="top">56%<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ER/PR Unknown<br></td><td class="Rrule" align="center" valign="top">43%<br></td><td class="Rrule" align="center" valign="top">44%<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">Previous Therapy</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adjuvant Only<br></td><td class="Rrule" align="center" valign="top">33%<br></td><td class="Rrule" align="center" valign="top">38%<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic +/- Adj.<br></td><td class="Rrule" align="center" valign="top">66%<br></td><td class="Rrule" align="center" valign="top">62%<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">Sites of Disease</span><br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" align="center" valign="top">&nbsp; <br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Soft Tissue<br></td><td class="Rrule" align="center" valign="top">56%<br></td><td class="Rrule" align="center" valign="top">50%<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bone<br></td><td class="Rrule" align="center" valign="top">50%<br></td><td class="Rrule" align="center" valign="top">55%<br></td></tr><tr class="Last"><td class="Lrule Rrule" valign="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Viscera<br></td><td class="Rrule" align="center" valign="top">40%<br></td><td class="Rrule" align="center" valign="top">44%<br></td></tr></tbody></table><p>Confirmed objective tumor response (complete response plus partial response) was the primary endpoint of the trials.&nbsp;Responses were measured according to the Union Internationale Contre le Cancer (UICC) criteria and verified by independent, blinded review. All responses were confirmed by a second evaluation 4-12 weeks after the documentation of the initial response.</p><p>Table 16&nbsp;shows the results for the first trial, with a minimum follow-up of 15 months, that compared letrozole tablets 0.5 mg, letrozole tablets 2.5 mg, and megestrol acetate 160 mg daily. (All analyses are unadjusted.)</p><p><span class="Bold">Table 16: Megestrol Acetate Study Results</span></p><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="Botrule First"><td class="Lrule Rrule" align="center" valign="top">&nbsp; <br></td><td class="Rrule" valign="top"><span class="Bold">Letrozole tablets</span><br><span class="Bold">0.5 mg </span><br><span class="Bold">N=188</span><br></td><td class="Rrule" valign="top"><span class="Bold">Letrozole tablets</span><br><span class="Bold">2.5 mg </span><br><span class="Bold">N=174</span><br></td><td class="Rrule" valign="top"><span class="Bold">megestrol </span><br><span class="Bold">acetate </span><br><span class="Bold">N=190</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" align="center" valign="top"><span class="Bold">Objective Response (CR + PR)</span><br></td><td class="Rrule" valign="top">22 (11.7%)<br></td><td class="Rrule" valign="top">41 (23.6%)<br></td><td class="Rrule" valign="top">31 (16.3%)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">Median Duration of Response</span><br></td><td class="Rrule" valign="top">552 days<br></td><td class="Rrule" valign="top">(Not reached)<br></td><td class="Rrule" valign="top">561 days<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">Median Time to Progression</span><br></td><td class="Rrule" valign="top">154 days<br></td><td class="Rrule" valign="top">170 days<br></td><td class="Rrule" valign="top">168 days<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">Median Survival</span><br></td><td class="Rrule" valign="top">633 days<br></td><td class="Rrule" valign="top">730 days<br></td><td class="Rrule" valign="top">659 days<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">Odds Ratio for Response</span><br></td><td class="Rrule" colspan="2" valign="top">Letrozole tablets 2.5:&nbsp;Letrozole tablets 0.5=2.33 <br>(95% CI: 1.32, 4.17); <span class="Italics">P</span>=0.004*<br></td><td class="Rrule" valign="top">Letrozole tablets 2.5: megestrol=1.58 <br>(95% CI: 0.94, 2.66); <span class="Italics">P</span>=0.08*<br></td></tr><tr class="Last"><td class="Lrule Rrule" valign="top"><span class="Bold">Relative Risk of Progression</span><br></td><td class="Rrule" colspan="2" valign="top">Letrozole tablets 2.5:&nbsp;Letrozole tablets 0.5=0.81 <br>(95% CI: 0.63, 1.03); <span class="Italics">P</span>=0.09*<br></td><td class="Rrule" valign="top">Letrozole tablets 2.5:&nbsp;megestrol=0.77 <br>(95% CI: 0.60, 0.98);&nbsp;<span class="Italics">P</span>=0.03* <br></td></tr></tbody></table>* two-sided <span class="Italics">P</span>-value<br>&nbsp;<br>The Kaplan-Meier curves for progression for the megestrol acetate study are shown in Figure 4.<br>&nbsp;<br><span class="Bold">Figure 4 Kaplan-Meier Estimates of Time to Progression (Megestrol Acetate Study)</span><br>&nbsp;<br><div class="Figure"><img src="image.cfm?id=45377&type=img&name=letrozole%2D05.jpg" alt="letrozole graph"></div>&nbsp;<p>The results for the study comparing letrozole tablets&nbsp;to aminoglutethimide, with a minimum follow-up of 9 months, are shown in Table 17. (Unadjusted analyses are used.)</p><p>&nbsp; </p><p><span class="Bold">Table&nbsp;17: Aminoglutethimide Study Results</span></p><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless"><tr class="Botrule First"><td class="Lrule Rrule" valign="top">&nbsp; <br></td><td class="Rrule" valign="top"><span class="Bold">Letrozole tablets </span>&nbsp;<br><span class="Bold">0.5 mg</span><br><span class="Bold">N=193</span><br></td><td class="Rrule" valign="top"><span class="Bold">Letrozole tablets</span><br><span class="Bold">2.5 mg</span><br><span class="Bold">N=185</span><br></td><td class="Rrule" valign="top"><span class="Bold">aminoglutethimide</span><br><span class="Bold">N=179</span><br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">Objective Response (CR&nbsp;+&nbsp;PR)</span><br></td><td class="Rrule" valign="top">34 (17.6%)<br></td><td class="Rrule" valign="top">34 (18.4%)<br></td><td class="Rrule" valign="top">22 (12.3%)<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">Median Duration of Response</span><br></td><td class="Rrule" valign="top">619 days<br></td><td class="Rrule" valign="top">706 days<br></td><td class="Rrule" valign="top">450 days<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">Median Time to Progression</span><br></td><td class="Rrule" valign="top">103 days<br></td><td class="Rrule" valign="top">123 days<br></td><td class="Rrule" valign="top">112 days<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">Median Survival</span><br></td><td class="Rrule" valign="top">636 days<br></td><td class="Rrule" valign="top">792 days<br></td><td class="Rrule" valign="top">592 days<br></td></tr><tr class="Botrule"><td class="Lrule Rrule" valign="top"><span class="Bold">Odds Ratio for Response</span><br></td><td class="Rrule" colspan="2" valign="top">Letrozole tablets 2.5:<br>Letrozole tablets 0.5=1.05<br>(95% CI: 0.62, 1.79);<span class="Italics"> P</span>=0.85*<br></td><td class="Rrule" valign="top">Letrozole tablets 2.5:<br>aminoglutethimide=1.61 <br>(95% CI: 0.90, 2.87); <span class="Italics">P</span>=0.11*<br></td></tr><tr class="Last"><td class="Lrule Rrule" valign="top"><span class="Bold">Relative Risk of Progression</span><br></td><td class="Rrule" colspan="2" valign="top">Letrozole tablets 2.5:<br>Letrozole tablets 0.5=0.86<br>(95% CI: 0.68, 1.11); <span class="Italics">P</span>=0.25*<br></td><td class="Rrule" valign="top">Letrozole tablets 2.5:&nbsp;<br>aminoglutethimide=0.74<br>(95% CI: 0.57, 0.94); <span class="Italics">P</span>=0.02*<br></td></tr></tbody></table><p>&nbsp;*two-sided <span class="Italics">P</span>-value</p><br>The Kaplan-Meier curves for progression for the aminoglutethimide study is shown in Figure 5<br>&nbsp;<br><span class="Bold">Figure 5&nbsp;Kaplan-Meier Estimates of Time to Progression (Aminoglutethimide Study)</span><br>&nbsp;<br><div class="Figure"><img src="image.cfm?id=45377&type=img&name=letrozole%2D06.jpg" alt="letrozole graph"></div></div></div><div class="Section"><a name="nlm34069-5"></a><a name="Section_16"></a><a name="section-14"></a><p></p><h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1><br>Packaged in HDPE bottles with a child resistant closure (30 tablets) and continuous thread closure (1000 tablets).<br>&nbsp;<br>2.5&nbsp;milligram tablets<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bottles of 30 tablets...................................................................................NDC 51991-759-33<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bottles of 1000 tablets............................................................................... NDC 51991-759-10<br>&nbsp;<br>Store at 25&deg;C (77&deg;F); excursions permitted to 15-30&deg;C (59-86&deg;F) [see USP Controlled Room Temperature].</div><div class="Section"><a name="nlm34076-0"></a><a name="Section_17"></a><a name="section-15"></a><p></p><h1>17 PATIENT COUNSELING INFORMATION</h1><br><span class="Bold">Information for Patients</span><br>&nbsp;<br>Pregnancy: Letrozole tablets are contraindicated in women of premenopausal endocrine status. The physician needs to discuss the necessity of adequate contraception with women who have the potential to become pregnant including women who are perimenopausal or who recently became postmenopausal, until their postmenopausal status is fully established.<br>&nbsp;<br>Fatigue and Dizziness: Since fatigue and dizziness have been observed with the use of letrozole tablets&nbsp;and somnolence was uncommonly reported, caution is advised when driving or using machinery.<br>&nbsp;<br>Bone Effects: Consideration should be given to monitoring bone mineral density.<br>&nbsp;<br>Distributed by:<br>Breckenridge Pharmaceutical, Inc.,<br>Boca Raton, FL33487<br><br>Manufactured by: <br>NATCO PHARMA LIMITED<br>Kothur - 509 228, <br>A.P., India.<br><br>00/Mar/2011</div><div class="Section"><a name="nlm51945-4"></a><a name="Section_19"></a><a name="section-16"></a><p></p><h1>Letrozole tablets 2.5 mg-Bottle of 30 tablets</h1><br>NDC 51991-759-33<br><br>Each film coated tablets contains: Letrozole 2.5 mg<br><br>Dosage: See package insert<br><br>Dispense in tight container(USP)<br><br>Store at 25&deg;C (77&deg;F); excursions permitted to 15-30&deg;C (59-86&deg;F).[See USP Controlled Room Temperature].<br><br><span class="Bold">Keep this and all the drugs out of reach of children.</span><br><div class="Figure"><img src="image.cfm?id=45377&type=img&name=letrozole%2D07.jpg" alt="letrozole tablets bottle of 30s container label"></div>&nbsp;</div><div class="Section"><a name="nlm51945-4"></a><a name="Unclassified_Section_29"></a><a name="section-17"></a><p></p><h1>Letrozole tablets 2.5 mg-Bottle of 1000 tablets</h1><br>NDC 51991-759-10<br>&nbsp;<br>Each film coated tablets contains: Letrozole 2.5 mg<br><br>Dosage: See package insert<br><br>Dispense in tight container(USP)<br><br>Store at 25&deg;C (77&deg;F); excursions permitted to 15-30&deg;C (59-86&deg;F).[See USP Controlled Room Temperature].<br><br><span class="Bold">Keep this and all the drugs out of reach of children.</span><br><div class="Figure"><img src="image.cfm?id=45377&type=img&name=letrozole%2D08.jpg" alt="letrozole tablets bottle of 1000 container label"></div></div></div><div class="DataElementsTables"><table width="100%" cellPadding="3" cellSpacing="0" class="contentTablePetite"><tbody><tr><td class="contentTableTitle"><strong>LETROZOLE&nbsp;							</strong><br><span class="contentTableReg">letrozole tablet</span></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="5" width="100%"><tr><td class="formHeadingTitle" colspan="4">Product Information</td></tr><tr class="formTableRowAlt"><td class="formLabel">Product Type</td><td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td><td class="formLabel">Item Code (Source)</td><td class="formItem">NDC:51991-759</td></tr><tr class="formTableRow"><td class="formLabel" width="30%">Route of Administration</td><td class="formItem">ORAL</td><td class="formLabel" width="30%">DEA Schedule</td><td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;							</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="3">Active Ingredient/Active Moiety</td></tr><tr><th scope="col" class="formTitle">Ingredient Name</th><th scope="col" class="formTitle">Basis of Strength</th><th scope="col" class="formTitle">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>LETROZOLE</strong> (LETROZOLE) </td><td class="formItem">LETROZOLE</td><td class="formItem">2.5&nbsp;mg</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="2">Inactive Ingredients</td></tr><tr><th scope="col" class="formTitle">Ingredient Name</th><th scope="col" class="formTitle">Strength</th></tr><tr class="formTableRowAlt"><td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>MAGNESIUM STEARATE</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>HYPROMELLOSE 2910 (6 MPA.S)</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>POLYETHYLENE GLYCOL 8000</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>SILICON DIOXIDE</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>TITANIUM DIOXIDE</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>FERRIC OXIDE YELLOW</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>STARCH, CORN</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRow"><td class="formItem"><strong>TALC</strong></td><td class="formItem">&nbsp;</td></tr><tr class="formTableRowAlt"><td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td><td class="formItem">&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="4">Product Characteristics</td></tr><tr class="formTableRowAlt"><td class="formLabel">Color</td><td class="formItem">YELLOW</td><td class="formLabel">Score</td><td class="formItem">no score</td></tr><tr class="formTableRow"><td class="formLabel">Shape</td><td class="formItem">ROUND (BICONVEX) </td><td class="formLabel">Size</td><td class="formItem">6mm</td></tr><tr class="formTableRowAlt"><td class="formLabel">Flavor</td><td class="formItem"></td><td class="formLabel">Imprint Code</td><td class="formItem">                                                      N;L                        </td></tr><tr class="formTableRow"><td class="formLabel">Contains</td><td class="formItem">&nbsp;&nbsp;&nbsp;&nbsp;</td></tr></table></td></tr><tr><td><table class="formTablePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingTitle" colspan="5">Packaging</td></tr><tr><th class="formTitle" width="1" scope="col">#</th><th class="formTitle" scope="col">Item Code</th><th class="formTitle" scope="col">Package Description</th><th class="formTitle" scope="col">Marketing Start Date</th><th class="formTitle" scope="col">Marketing End Date</th></tr><tr class="formTableRowAlt"><th class="formItem" scope="row">1</th><td class="formItem">NDC:51991-759-33</td><td class="formItem">30  in 1 BOTTLE</td><td class="formItem"></td><td class="formItem"></td></tr><tr class="formTableRow"><th class="formItem" scope="row">2</th><td class="formItem">NDC:51991-759-10</td><td class="formItem">1000  in 1 BOTTLE</td><td class="formItem"></td><td class="formItem"></td></tr></table></td></tr><tr><td></td></tr><tr><td class="normalizer"><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Marketing Information</span></td></tr><tr><th class="formTitle" scope="col">Marketing Category</th><th class="formTitle" scope="col">Application Number or Monograph Citation</th><th class="formTitle" scope="col">Marketing Start Date</th><th class="formTitle" scope="col">Marketing End Date</th></tr><tr class="formTableRowAlt"><td class="formItem">ANDA</td><td class="formItem">ANDA200161</td><td class="formItem">06/04/2011</td><td class="formItem"></td></tr></table></td></tr></tbody></table><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Labeler -&nbsp;</span>Breckenridge Pharmaceutical, Inc.							(150554335)						</td></tr></table><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Registrant -&nbsp;</span>Natco Pharma Ltd (918588174)</td></tr></table><table class="formTableMorePetite" cellspacing="0" cellpadding="3" width="100%"><tr><td class="formHeadingReg" colspan="4"><span class="formHeadingTitle">Establishment</span></td></tr><tr><th class="formTitle" scope="col">Name</th><th class="formTitle" scope="col">Address</th><th class="formTitle" scope="col">ID/FEI</th><th class="formTitle" scope="col">Business Operations</th></tr><tr class="formTableRowAlt"><td class="formItem">Natco Pharma Ltd</td><td class="formItem"></td><td class="formItem">918588174</td><td class="formItem">MANUFACTURE</td></tr></table></div><p><div class="EffectiveDate">Revised: 6/2011<div class="DocumentMetadata"><div><a href="javascript:toggleMixin();">Document Id: </a>053eb06e-d89a-4dcf-a86a-f9ad1077f52e</div><div>Set id: 63e54b62-a30d-4a56-9215-75e7a0b0bf02</div><div>Version: 2</div><div>Effective Time: 20110607</div></div></div>&nbsp;<div class="DistributorName">Breckenridge Pharmaceutical, Inc.</div></p>			</div>			</div>			<div id="nlmfooter">	<a href="http://www.nlm.nih.gov">		<img  src="/dailymed/images/logo.gif"		alt="Visit The National Library of Medicine" />	</a>	<a href="http://www.nlm.nih.gov/copyright.html">Copyright</a>,	<a href="http://www.nlm.nih.gov/privacy.html">Privacy</a>,	<a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a><br />	<a href="http://www.nlm.nih.gov">U.S. National Library of Medicine</a>, 8600 Rockville Pike, Bethesda, MD 20894<br />	<a href="http://www.nih.gov/">National Institutes of Health</a>,	<a href="http://www.hhs.gov/">Health &amp; Human Services</a></div>		</body>	</html>